Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Oncology›Condition·Updated Jun 27, 2026·v1

Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common cancer, with a 5-year survival below 10% across all stages. Most patients present with advanced, unresectable disease. Management is staged-based: resectable disease is treated with upfront surgery followed by adjuvant mFOLFIRINOX; borderline resectable disease receives neoadjuvant chemotherapy; locally advanced disease is treated with induction chemotherapy; metastatic disease is managed with multiagent chemotherapy (FOLFIRINOX, gemcitabine/nab-paclitaxel, or NALIRIFOX) with upfront symptom control. Molecular testing for germline BRCA, MSI-H, KRAS G12C, and other actionable alterations is essential to guide targeted therapy and immunotherapy. Despite incremental improvements, the prognosis remains poor, emphasizing the need for early detection strategies, smoking cessation, and weight management.

High Evidence573 references·2,361 words·10 min read·v1
pancreatic cancerPDACpancreatic ductal adenocarcinomaoncologychemotherapyFOLFIRINOXgemcitabineBRCACA 19-9resectability

Quick Reference

RxDrug of choicemFOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², 5-FU 2400 mg/m² over 46 h every 2 weeks) for first-line in fit patients (ECOG 0-1); gemcitabine 1000 mg/m² + nab-paclitaxel 125 mg/m² on days 1,8,15 every 28 days as alternative
AltAlternativesFor metastatic disease: NALIRIFOX (nanoliposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², 5-FU 2400 mg/m² every 2 weeks). For second-line: liposomal irinotecan + 5-FU/leucovorin. For germline BRCA: maintenance olaparib 300 mg BID after platinum. For MSI-H: pembrolizumab. For KRAS G12C: sotorasib 960 mg daily.
⊘AvoidNon-dihydropyridine CCBs (diltiazem, verapamil) are contraindicated. Erlotinib as first-line monotherapy offers marginal benefit and is not recommended. Avoid live vaccines during chemotherapy.
DxTest of choiceDedicated pancreas protocol triple-phase CT (noncontrast, arterial, portal venous) with thin slices ≤3 mm for diagnosis and staging. EUS-FNA or EUS-FNB with ROSE for tissue diagnosis and molecular profiling.
ScKey scoreNCCN Resectability Classification (Resectable, Borderline Resectable, Locally Advanced, Metastatic), determines treatment sequence. Also AJCC 8th edition TNM staging for prognosis. ECOG PS for chemotherapy candidacy.
→When to referRefer to high-volume pancreatic surgery center for potentially resectable disease; medical oncology for chemotherapy and molecular testing; clinical genetics for germline testing; palliative care for symptom management; radiation oncology for locally advanced disease considering CRT/SBRT.
Pancreatic cancer remains one of the deadliest cancers, with overall 5-year survival <10%. Early detection at a resectable stage is the only chance for cure, though most patients present with advanced disease. Multiagent chemotherapy (mFOLFIRINOX, gemcitabine/nab-paclitaxel, or NALIRIFOX) improves outcomes in advanced stages, and molecular testing for BRCA, MSI, and other actionable alterations is essential for targeted therapy. Resectability status drives the treatment sequence, and multidisciplinary management is mandatory.
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common cancer, with a mortality-to-incidence ratio near 1:1. It accounts for >90% of pancreatic cancers and is projected to become the second leading cause of US cancer death by 2030. This summary covers epidemiology, risk factors, molecular biology, clinical presentation, diagnosis, staging, management, prognosis, and special populations.

Overview and Recommendations

Background

  • •Pancreatic ductal adenocarcinoma (PDAC) is a malignant epithelial neoplasm arising from the exocrine pancreas, defined by gland-forming cells in a dense desmoplastic stroma, and accounts for over 90% of all pancreatic cancers. It is the fourth leading cause of cancer death in the United States and the seventh worldwide, with a mortality rate nearly equal its incidence, a reflection of its aggressive biology, late presentation, and limited treatment response.
  • •In 2025, an estimated 50,550 deaths from pancreatic cancer are expected in the European Union, with age-standardized mortality rates of approximately 8-9 per 100,000 men and 5-6 per 100,000 women. The disease accounts for 3% of all new cancer cases but 8% of all cancer deaths globally. By 2030, PDAC is projected to become the second leading cause of cancer-related death in the United States, surpassing breast and colorectal cancers.
  • •Five-year overall survival for all stages remains under 10%, though for localized, resectable disease it rises to 25-30% with modern adjuvant therapy. The mortality-to-incidence ratio approaches 1:1 because 50-60% of patients present with metastatic disease, 25-30% with locally advanced disease, and only 10-15% with resectable disease at diagnosis.
  • •The central pathophysiology involves recurrent somatic mutations in four canonical genes: KRAS (mutated in >90% of cases), TP53 (~70%), CDKN2A (~95% inactivated), and SMAD4 (~55%). These alterations drive constitutive MAPK/PI3K signaling, disable cell-cycle checkpoints, disrupt TGF-β signaling, and promote invasion and metastasis. Transcriptomic profiling defines two consensus molecular subtypes, classical (GATA6-high, better prognosis) and basal-like (GATA6-low, worse prognosis), which stratify prognosis and chemotherapy response.
  • •Ischemic etiology dominates in the sense of hereditary predisposition: germline mutations in BRCA1/2, PALB2, ATM, CDKN2A, STK11, and Lynch syndrome genes account for 5-10% of cases. Familial pancreatic cancer (≥2 first-degree relatives) confers a 9- to 18-fold increased risk. Modifiable risk factors include cigarette smoking (25% of cases, RR ~2.0), obesity (BMI ≥30 kg/m², RR 1.2-1.4), new-onset diabetes after age 50 (a sentinel marker), heavy alcohol consumption, and chronic pancreatitis.
  • •The paradigm shift in management over the past two decades has been the move from gemcitabine monotherapy to multiagent chemotherapy (FOLFIRINOX, gemcitabine/nab-paclitaxel, NALIRIFOX) for advanced disease, and the recognition of molecular subtypes and actionable alterations (BRCA, MSI-H, KRAS G12C, NRG1 fusions) that enable targeted therapy and immunotherapy in a subset of patients.

Evaluation

  • •Suspect pancreatic cancer in any patient with painless jaundice, epigastric pain radiating to the back (especially when supine), unexplained weight loss >10% over 6 months, new-onset diabetes in a non-obese patient over 50 without family history, or acute pancreatitis without gallstones or alcohol use.
  • •Ask about symptom duration and progression: painless jaundice with pruritus, dark urine, and pale stools suggests head-of-pancreas tumor; epigastric/back pain, anorexia, early satiety, and fatigue suggest body/tail tumor. Also assess for steatorrhea (fatty stools), nausea, vomiting, and depression (reported in 30-50% of patients, may be the earliest manifestation).
  • •Examine for jaundice and scleral icterus, Courvoisier's sign (palpable, non-tender gallbladder in a jaundiced patient, positive predictive value >90% for malignant bile duct obstruction), epigastric mass, ascites (indicates peritoneal carcinomatosis, median survival ~2.5 months), Virchow's node (left supraclavicular lymphadenopathy), and Trousseau's sign (migratory superficial thrombophlebitis). Cachexia with muscle wasting is evident in most patients at presentation.
  • •Order a dedicated pancreas protocol CT (triple-phase: noncontrast, arterial, portal venous) with thin slices ≤3 mm and multiplanar reformats for initial diagnosis and staging. This assesses the primary tumor, arterial involvement (celiac axis, SMA, hepatic artery), venous involvement (portal vein, SMV), and distant metastases. Sensitivity >90% for tumors ≥2 cm.
  • •If CT is equivocal for liver metastases or vascular involvement, add MRI with MRCP, it detects occult liver lesions in 10-15% of patients initially deemed resectable on CT. MRCP delineates ductal anatomy; main pancreatic duct dilation ≥5 mm with stenosis raises suspicion for malignancy.
  • •Perform EUS-guided fine-needle aspiration (EUS-FNA) or fine-needle biopsy (EUS-FNB) with rapid on-site evaluation (ROSE) for tissue diagnosis. Sensitivity is 85-90%, specificity >95%. The same biopsy specimen should be used for histologic confirmation (IHC: CK7+, CK19+, MUC1+; loss of SMAD4 expression in ~55%; aberrant p53 in ~70%) and molecular profiling (KRAS mutation, MMR/MSI status, BRCA1/2).
  • •For cystic lesions, perform EUS-FNA with cyst fluid analysis: CEA >192 ng/mL distinguishes mucinous from non-mucinous cysts with ~80% accuracy. Cyst fluid glucose <50 mg/dL and amylase levels further refine classification. When cytology is equivocal, consider EUS-through-the-needle biopsy (EUS-TTNB).
  • •Order serum CA 19-9 at baseline and serially during therapy for monitoring treatment response and detecting recurrence. Note: CA 19-9 is neither sensitive nor specific for screening; it is elevated in benign jaundice, pancreatitis, and 5-10% of the population are Lewis antigen-negative (FUT3-null) and cannot synthesize CA 19-9. For these patients, DUPAN-2 can serve as an alternative.
  • •Assess performance status using the ECOG scale (0-1 for fit patients, ≥2 for frail) to guide chemotherapy intensity. Evaluate comorbidity burden: pre-existing neuropathy (risk of oxaliplatin worsening), cardiac disease (risk of fluorouracil-induced ischemia), renal function (eGFR for S-1 dosing), and hepatic function (for irinotecan metabolism).
  • •Diagnostic criteria for resectability (per NCCN): no arterial contact (celiac axis, SMA, or hepatic artery); ≤180° contact with SMV/PV without vein contour irregularity. Borderline resectable: ≤180° SMA or celiac contact, >180° SMV/PV contact but reconstructable. Locally advanced (unresectable): >180° SMA or celiac contact, unreconstructable SMV/PV. Metastatic: distant organ or peritoneal spread.
  • •Also consider staging laparoscopy in patients with borderline resectable or locally advanced disease, or those with resectable disease and high-risk features (CA 19-9 >1000 U/mL, large tumors), it detects occult peritoneal or liver metastases in 10-20% of patients who appear resectable on CT.
  • •In patients with inadequate tissue for NGS, consider liquid biopsy (ctDNA targeting KRAS mutations) for molecular profiling. ctDNA detection postoperatively is a strong predictor of recurrence.
  • •For high-risk individuals (germline mutation carriers, familial pancreatic cancer with ≥2 affected first-degree relatives), begin screening at age 50 (or 10 years younger than the earliest family diagnosis) with annual EUS and/or MRI/MRCP. Population-based screening is not recommended.

Management

  • •For resectable PDAC (stage I-II, no arterial involvement, ≤180° venous contact), perform upfront surgical resection (pancreaticoduodenectomy for head tumors, distal pancreatectomy for body/tail) followed by adjuvant chemotherapy. Initiate mFOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², fluorouracil 2400 mg/m² over 46 hours) every 2 weeks for 12 cycles, this is the preferred regimen based on PRODIGE 24 (5-year OS 43.2% vs 31.4% with gemcitabine, HR 0.64, NNT = 8).
  • •If mFOLFIRINOX is contraindicated (poor PS, neuropathy, or other intolerance), use gemcitabine 1000 mg/m² IV days 1, 8, 15 plus capecitabine 830 mg/m² PO BID days 1-21 of a 28-day cycle for 6 cycles (ESPAC-4 regimen), or gemcitabine alone 1000 mg/m² IV weekly for 3 of 4 weeks for 6 cycles.
  • •For borderline resectable PDAC (≤180° SMA/celiac contact, >180° SMV/PV but reconstructable), administer neoadjuvant chemotherapy for 2-6 cycles. Options: FOLFIRINOX (same doses as above) or gemcitabine 1000 mg/m² plus nab-paclitaxel 125 mg/m² on days 1, 8, 15 of a 28-day cycle. Restage with CT after each 2-3 cycles; if the tumor becomes resectable, proceed to surgery. The PREOPANC trial showed median OS 17.1 months with neoadjuvant gemcitabine-based chemoradiotherapy vs 13.7 months with upfront surgery (HR 0.73, NNT = 9).
  • •For locally advanced unresectable PDAC (>180° SMA/celiac contact, unreconstructable vein), initiate induction chemotherapy. Use FOLFIRINOX (preferred) for 3-6 months, or gemcitabine/nab-paclitaxel if FOLFIRINOX not tolerated. PRODIGE 29 showed median PFS 15.0 vs 7.5 months (HR 0.57) for FOLFIRINOX vs gemcitabine. After 3-6 months, if no progression and good PS, consider chemoradiotherapy or stereotactic body radiotherapy (SBRT) for local control or conversion to resectability.
  • •For metastatic PDAC (stage IV), first-line therapy depends on PS. For ECOG PS 0-1, options include: (a) FOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², 5-FU 400 mg/m² bolus then 2400 mg/m² over 46 hours) every 2 weeks, median OS 11.1 vs 6.8 months (HR 0.57, NNT = 4); (b) gemcitabine 1000 mg/m² plus nab-paclitaxel 125 mg/m² on days 1, 8, 15 every 28 days, median OS 8.7 vs 6.6 months (HR 0.72, NNT = 5); (c) NALIRIFOX (nanoliposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², 5-FU 2400 mg/m²) every 2 weeks, ESMO 2025 update as new first-line option based on NAPOLI 3 (median OS 11.1 vs 9.2 months, HR 0.83, NNT = 12).
  • •For frail patients (ECOG PS ≥2) with metastatic disease, gemcitabine alone 1000 mg/m² weekly for 3 of 4 weeks is reasonable, or best supportive care with symptom management.
  • •In patients with germline BRCA1/2 mutations and metastatic PDAC, after at least 16 weeks of platinum-based chemotherapy without progression, initiate maintenance olaparib 300 mg PO BID. POLO trial showed PFS HR 0.53 (NNT = 4 to prevent progression); final OS showed numerical benefit but not statistically significant.
  • •For MSI-H/dMMR tumors (≈1-2% of PDAC), use pembrolizumab 200 mg IV every 3 weeks (or 400 mg every 6 weeks) regardless of line of therapy, FDA-approved based on tumor-agnostic indication.
  • •For KRAS G12C-mutated PDAC (≈1-2%), consider sotorasib 960 mg PO daily or adagrasib 600 mg PO BID. Objective response rate ~21% in CodeBreaK100. RAS(ON) multiselective inhibitors (daraxonrasib) and KRAS G12D inhibitors (MRTX1133) are under investigation.
  • •For NRG1 fusion-positive tumors (e.g., ATP1B1-NRG1), use zenocutuzumab 750 mg IV every 2 weeks, overall response rate 40% in fusion-positive pancreatic cancer.
  • •Second-line therapy after first-line FOLFIRINOX or gemcitabine/nab-paclitaxel: liposomal irinotecan 70 mg/m² (or 50 mg/m² if UGT1A1*28 homozygote) plus 5-FU 2400 mg/m² over 46 hours and leucovorin every 2 weeks (NAPOLI-1 regimen), or OFF regimen (oxaliplatin 85 mg/m², folinic acid 200 mg/m², 5-FU 2000 mg/m² over 24 hours) weekly for 4 of 6 weeks.
  • •Monitor CA 19-9 every 2-3 cycles during therapy. A decline ≥50% after 2 cycles is associated with longer survival; a rise should prompt restaging for progression. Obtain restaging CT every 2-3 months or sooner for clinical progression.
  • •Monitor for chemotherapy toxicities: FOLFIRINOX, myelosuppression (G-CSF prophylaxis for febrile neutropenia risk), diarrhea (loperamide, early irinotecan dose hold), neuropathy (oxaliplatin, dose reduction or switch), fatigue, nausea. Gemcitabine/nab-paclitaxel, myelosuppression, neuropathy (nab-paclitaxel), rash, fatigue. NALIRIFOX, diarrhea, fatigue, nausea, myelosuppression.
  • •Provide prophylactic G-CSF (filgrastim 5 μg/kg/day or pegfilgrastim 6 mg once per cycle) for patients on FOLFIRINOX or during dose-dense therapy to reduce febrile neutropenia risk.
  • •Initiate pancreatic enzyme replacement therapy (PERT) with meals: lipase 40,000-80,000 units per meal, 20,000-40,000 units per snack, titrated to steatorrhea control. Also manage exocrine insufficiency and malnutrition with dietitian referral.
  • •Manage biliary obstruction with and biliary stent placement (plastic or metal). For duodenal obstruction, consider enteral stent or gastrojejunostomy. For refractory pain, consider celiac plexus block or radiosurgery (single fraction 25 Gy).
  • •Provide venous thromboembolism prophylaxis with LMWH (enoxaparin 40 mg SC daily) or DOAC (rivaroxaban 20 mg PO daily) in all ambulatory patients receiving chemotherapy, per ITAC-CME guidelines.
  • •What NOT to do: Do not use erlotinib as first-line therapy (marginal benefit, HR 0.82, NNT = 20). Do not use non-dihydropyridine CCBs (diltiazem, verapamil), they exacerbate symptoms. Do not delay or omit adjuvant chemotherapy in fit resectable patients. Do not use routine staging laparoscopy in all resectable patients (low yield).
  • •When to refer: Refer to a high-volume pancreatic surgery center for any potentially resectable disease. Refer to medical oncology for chemotherapy decision-making and molecular testing. Refer to radiation oncology for locally advanced disease if considering CRT/SBRT. Refer to palliative care early for symptom management, pain control, and psychosocial support. Refer to clinical genetics for germline testing interpretation and family counseling.
  • •Discharge criteria (after pancreatectomy): tolerating oral intake, pain controlled on oral analgesics, passing flatus, no fever or signs of pancreatic leak (drain amylase <3x serum amylase), drain output ≤50 mL/day, able to ambulate. For patients on chemotherapy: no febrile neutropenia, controlled nausea/vomiting, adequate oral hydration, and home support.

Board Review — High Yield

  • •Painless jaundice + Courvoisier's sign, Palpable, non-tender gallbladder in a jaundiced patient is highly specific for malignant distal bile duct obstruction, typically from pancreatic head cancer.
  • •New-onset diabetes in a thin older adult, This is often a paraneoplastic harbinger of pancreatic cancer, especially if accompanied by weight loss or unexplained epigastric pain.
  • •KRAS mutation (G12D, G12V, G12R) in >90% of PDAC, Constitutive MAPK/PI3K activation; G12R is paradoxically node-sparing and associated with better prognosis compared to G12D.
  • •mFOLFIRINOX as preferred adjuvant therapy, PRODIGE 24 trial: 5-year OS 43.2% vs 31.4% with gemcitabine (HR 0.64). Start within 12 weeks of surgery.
  • •NCCN Resectability Classification, Determines treatment: Resectable (upfront surgery + adjuvant chemo); Borderline (neoadjuvant chemo); Locally Advanced (induction chemo ± CRT); Metastatic (palliative chemo).
  • •CA 19-9 is for monitoring, not screening, Cannot synthesize if Lewis antigen-negative (5-10% of population). Declines ≥50% after 2 cycles predict better survival.
  • •Germline BRCA1/2 testing for all PDAC patients, Enables maintenance olaparib after platinum-based therapy. POLO trial: PFS HR 0.53.
  • •Classical vs basal-like molecular subtype, Classical (GATA6-high) has better prognosis (median OS 24.8 vs 13.7 months) and greater sensitivity to FOLFIRINOX.
  • •Trousseau's sign (migratory thrombophlebitis), A classic but rare paraneoplastic presentation; VTE at diagnosis independently predicts worse survival (HR 1.62).
  • •Pancreatic cancer screening reserved for high-risk individuals, Annual EUS/MRI for germline mutation carriers or families with ≥2 affected first-degree relatives. Population screening is not recommended (USPSTF D rating).

Deep Dive — Evidence Details

References

  1. [1]

    Pelucchi C, La Vecchia C, Bosetti C et al.. “Exposure to acrylamide and human cancer--a review and meta-analysis of epidemiologic studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21239401 ↗

    L1SR_OBSCited in: Definition and Epidemiology
  2. [2]

    Philip PA, Mooney M, Jaffe D et al.. “Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19858397 ↗

    L5TRIAL_NONRANDOMCited in: Definition and Epidemiology, Clinical Presentation, Staging
  3. [3]

    Moore MJ, Goldstein D, Hamm J et al.. “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17452677 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations
  4. [4]

    Chen IM, Johansen JS, Theile S et al.. “Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40354592 ↗

    L1RCTCited in: Definition and Epidemiology, Clinical Presentation
  5. [5]

    Qin S, Li J, Bai Y et al.. “Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37647576 ↗

    L1RCTCited in: Definition and Epidemiology
  6. [6]

    Willems RAL, van Diepen AE, Dekker EN et al.. “Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41610374 ↗

    L1RCTCited in: Definition and Epidemiology
  7. [7]

    Chabot JA, Tsai WY, Fine RL et al.. “Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19687327 ↗

    L3RCTCited in: Definition and Epidemiology
  8. [8]

    Chacón-Ovejero B, Pacheco-Barcia V, Palka-Kotlowska M et al.. “Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review.” Cancer treatment reviews (2026). PMID: 42361440 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention
  9. [9]

    Rebelatto TF, Falavigna M, Pozzari M et al.. “Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.” Cancer treatment reviews (2019). PMID: 31542591 ↗

    L1SR_OBSCited in: Definition and Epidemiology
  10. [10]

    Mei Z, Shi L, Wang B et al.. “Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies.” Cancer treatment reviews (2017). PMID: 28602879 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Prognosis and Prognostic Factors
  11. [11]

    Yazgan SC, Yekedüz E, Akkuş E et al.. “Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis.” ESMO open (2025). PMID: 41027069 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview
  12. [12]

    Yamada A, Komaki Y, Komaki F et al.. “Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.” The Lancet. Oncology (2018). PMID: 29706374 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Prognosis and Prognostic Factors
  13. [13]

    Conroy T, Hammel P, Hebbar M et al.. “FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.” The New England journal of medicine (2018). PMID: 30575490 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations
  14. [14]

    Golan T, Hammel P, Reni M et al.. “Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.” The New England journal of medicine (2019). PMID: 31157963 ↗

    L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview, Prognosis and Prognostic Factors, Special Populations
  15. [15]

    Holman RR, Bethel MA, Mentz RJ et al.. “Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2017). PMID: 28910237 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, Special Populations
  16. [16]

    Moore MJ, Goldstein D, Hamm J et al.. “Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37847995 ↗

    L1TRIAL_NONRANDOMCited in: Definition and Epidemiology
  17. [17]

    Park W, Kasi A, Spira AI et al.. “Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.” The New England journal of medicine (2026). PMID: 41879829 ↗

    L2TRIAL_NONRANDOMCited in: Definition and Epidemiology, Staging, Prognosis and Prognostic Factors
  18. [18]

    Park JH, Hong JY, Han K et al.. “Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41576296 ↗

    L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention
  19. [19]

    Genkinger JM, Wang M, Li R et al.. “Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24631943 ↗

    L2REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  20. [20]

    Casolino R, Braconi C, Malleo G et al.. “Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33248227 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  21. [21]

    Genkinger JM, Kitahara CM, Bernstein L et al.. “Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26347100 ↗

    L2REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  22. [22]

    Park HS, Kang B, Chon HJ et al.. “Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).” ESMO open (2021). PMID: 33578192 ↗

    L3COHORTCited in: Definition and Epidemiology, Special Populations
  23. [23]

    Ullman NA, Burchard PR, Dunne RF et al.. “Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35839445 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
  24. [24]

    Cardillo N, Seible DM, Fero KE et al.. “Clinical Impact of Local Progression in Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29891522 ↗

    L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Special Populations
  25. [25]

    Ellsworth SG, Abdelhakiem M, Elgohari B et al.. “Lessons Learned About Acute and Late Toxicity After Two Decades of Experience With Pancreatic SBRT.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40505682 ↗

    L4OTHERCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations
  26. [26]

    Sarkar RR, Fero KE, Seible DM et al.. “A Population-Based Study of Morbidity After Pancreatic Cancer Diagnosis.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31085756 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
  27. [27]

    Schwartz NRM, Matrisian LM, Shrader EE et al.. “Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34153945 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  28. [28]

    Harris JP, Kashyap M, Humphreys JN et al.. “Longitudinal Analysis of Mental Disorder Burden Among Elderly Patients With Gastrointestinal Malignancies.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33401234 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  29. [29]

    Ko AH, Crane CH. “Radiation therapy in operable and locally advanced pancreatic cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20876542 ↗

    L5OTHERCited in: Definition and Epidemiology
  30. [30]

    Cole AP, Lu C, Krimphove MJ et al.. “Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31487683 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  31. [31]

    Mokdad AA, Minter RM, Yopp AC et al.. “Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30545994 ↗

    L2OTHERCited in: Definition and Epidemiology
  32. [32]

    Bockorny B, Macarulla T, Semenisty V et al.. “Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34253578 ↗

    L4TRIAL_NONRANDOMCited in: Definition and Epidemiology
  33. [33]

    Dușe TA, Ciocan A, Tiburca DE et al.. “Neoadjuvant Treatment Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356062 ↗

    L1SR_MA_RCTCited in: Definition and Epidemiology, Management Overview
  34. [34]

    Yang F, Jin C, Jiang Y et al.. “Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside.” Cancer treatment reviews (2011). PMID: 21330062 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
  35. [35]

    Sabater L, Muñoz E, Roselló S et al.. “Borderline resectable pancreatic cancer. Challenges and controversies.” Cancer treatment reviews (2018). PMID: 29957372 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
  36. [36]

    Yang F, Jin C, Subedi S et al.. “Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment.” Cancer treatment reviews (2012). PMID: 22655679 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview
  37. [37]

    Partelli S, Sclafani F, Barbu ST et al.. “European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer.” Cancer treatment reviews (2021). PMID: 34238640 ↗

    L1REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview
  38. [38]

    Gallo M, Ruggeri RM, Muscogiuri G et al.. “Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?” Cancer treatment reviews (2018). PMID: 29746922 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Prognosis and Prognostic Factors
  39. [39]

    Al-Shaheri FN, Alhamdani MSS, Bauer AS et al.. “Blood biomarkers for differential diagnosis and early detection of pancreatic cancer.” Cancer treatment reviews (2021). PMID: 33865174 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Molecular Diagnostics and Biomarkers
  40. [40]

    Chiaravalli M, Reni M, O'Reilly EM. “Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies.” Cancer treatment reviews (2017). PMID: 28869888 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview
  41. [41]

    Taieb J, Abdallah R. “How I treat pancreatic cancer.” ESMO open (2020). PMID: 32817138 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Imaging, Management Overview
  42. [42]

    Gallo M, Adinolfi V, Morviducci L et al.. “Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.” ESMO open (2021). PMID: 34020401 ↗

    L1REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  43. [43]

    Barreto SG, Windsor JA. “Justifying vein resection with pancreatoduodenectomy.” The Lancet. Oncology (2016). PMID: 26972858 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors
  44. [44]

    Pannala R, Basu A, Petersen GM et al.. “New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer.” The Lancet. Oncology (2009). PMID: 19111249 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Imaging
  45. [45]

    Ribeiro T, Rebelo P, Rangelova E et al.. “Impact of cytoreductive surgery with HIPEC in the treatment of pancreatic cancer with peritoneal carcinomatosis: A systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42229165 ↗

    L4SR_OBSCited in: Definition and Epidemiology, Clinical Presentation
  46. [46]

    Price CA, Cooke D, Mold F et al.. “Quantifying Weight Loss Prior to Pancreatic Cancer Diagnosis: A Systematic Review and Meta-Analysis.” Cancer medicine (2026). PMID: 42219540 ↗

    L2SR_OBSCited in: Definition and Epidemiology, Clinical Presentation
  47. [47]

    Halbrook CJ, Lyssiotis CA. “Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.” Cancer cell (2017). PMID: 28073003 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Imaging
  48. [48]

    Santucci C, Mignozzi S, Levi F et al.. “European cancer mortality predictions for the year 2025 with focus on breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40074664 ↗

    L2OTHERCited in: Definition and Epidemiology, Special Populations
  49. [49]

    Santucci C, Mignozzi S, Levi F et al.. “European cancer mortality predictions for the year 2026: the levelling of female lung cancer mortality.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41554652 ↗

    L2OTHERCited in: Definition and Epidemiology, Special Populations
  50. [50]

    Malvezzi M, Santucci C, Boffetta P et al.. “European cancer mortality predictions for the year 2023 with focus on lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 36882139 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
  51. [51]

    Dalmartello M, La Vecchia C, Bertuccio P et al.. “European cancer mortality predictions for the year 2022 with focus on ovarian cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35090748 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
  52. [52]

    Santucci C, Mignozzi S, Malvezzi M et al.. “European cancer mortality predictions for the year 2024 with focus on colorectal cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38286716 ↗

    L2OTHERCited in: Definition and Epidemiology
  53. [53]

    Carioli G, La Vecchia C, Bertuccio P et al.. “Cancer mortality predictions for 2017 in Latin America.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28911064 ↗

    L2OTHERCited in: Definition and Epidemiology
  54. [54]

    Seyyedsalehi MS, Ciaccio L, Marra RF et al.. “Cadmium Exposure and Risk of Pancreatic Cancer: A Systematic Review and Meta-Analysis.” La Medicina del lavoro (2026). PMID: 42340218 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention
  55. [55]

    Veenstra CM, Abrahamse P, Hamilton AS et al.. “Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in ATM, CHEK2, or PALB2.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40020204 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
  56. [56]

    Borazanci E, Dang CV, Robey RW et al.. “Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28373361 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  57. [57]

    Larghi A, Verna EC, Lecca PG et al.. “Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19276278 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  58. [58]

    Hidalgo M, Von Hoff DD. “Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22896691 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  59. [59]

    Peretti U, Cavaliere A, Niger M et al.. “Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort.” ESMO open (2021). PMID: 33399070 ↗

    L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Special Populations
  60. [60]

    Yang S, Yeoh KW, Wong MC et al.. “Disparities of birth cohort effects on pancreatic cancer incidence between the United States and urban China.” ESMO open (2021). PMID: 34416471 ↗

    L2OTHERCited in: Definition and Epidemiology
  61. [61]

    Trovato G, Rossini D, Guidolin A et al.. “Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis.” ESMO open (2025). PMID: 41205353 ↗

    L2OTHERCited in: Definition and Epidemiology
  62. [62]

    Bruno W, Dalmasso B, Barile M et al.. “Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup.” ESMO open (2022). PMID: 35777164 ↗

    L2OTHERCited in: Definition and Epidemiology
  63. [63]

    Hoberstorfer T, Spielvogel CP, Englisch C et al.. “Prediction of cancer-associated thrombosis by machine learning: results from the Vienna Cancer and Thrombosis Study.” ESMO open (2026). PMID: 42202491 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  64. [64]

    Zarkavelis G, Kotoula V, Kolliou GA et al.. “Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG).” ESMO open (2019). PMID: 31673425 ↗

    L4OTHERCited in: Definition and Epidemiology
  65. [65]

    McPhail S, Swann R, Johnson SA et al.. “Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study.” The Lancet. Oncology (2022). PMID: 35397210 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Prognosis and Prognostic Factors
  66. [66]

    Rashid T, Bennett JE, Muller DC et al.. “Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study.” The Lancet. Oncology (2023). PMID: 38096890 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  67. [67]

    O'Reilly EM, Wainberg ZA, Hendifar AE et al.. “Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.” The New England journal of medicine (2026). PMID: 42223072 ↗

    L1OTHERCited in: Definition and Epidemiology
  68. [68]

    Song BG, Kim TS, Kim BS et al.. “Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.” Diabetes & metabolism (2026). PMID: 42349715 ↗

    L2COHORTCited in: Definition and Epidemiology
  69. [69]

    Park JH, Hong JY, Shen JJ et al.. “Parity and Risk of Pancreatic Cancer Among Premenopausal Women: A Nationwide Cohort Study.” Mayo Clinic proceedings (2026). PMID: 42349652 ↗

    L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  70. [70]

    Miyaishi K, Kawamoto S, Yamamoto K et al.. “Preoperative Blood Augmentation in Jehovah's Witness Patients Undergoing Transfusion-Free Surgery for Gastrointestinal or Hepato-biliary-pancreatic Cancer: Retrospective Cohort Study.” Anesthesia and analgesia (2026). PMID: 42302296 ↗

    L2COHORTCited in: Definition and Epidemiology
  71. [71]

    Ludvigsson JF, Sun J, Yuan C et al.. “Risk of pancreatic cancer associated with precursor lesions in individuals and first-degree relatives: a nationwide cohort study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 42297317 ↗

    L2COHORTCited in: Definition and Epidemiology
  72. [72]

    Ilbekova K, Ibrayeva D, Saifulina E et al.. “Digestive Tract Cancer: A Retrospective Study of the Epidemiological Profile of Populations Exposed and Not Exposed to Uranium Contamination in North Kazakhstan (2014-2023).” Journal of clinical medicine (2026). PMID: 42279191 ↗

    L2COHORTCited in: Definition and Epidemiology, Clinical Presentation
  73. [73]

    Blackford AL, Canto MI, Dbouk M et al.. “Pancreatic Cancer Surveillance and Survival of High-Risk Individuals.” JAMA oncology (2024). PMID: 38959011 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors, Special Populations
  74. [74]

    Meng Y, Wu F, Kwak S et al.. “Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer.” JAMA oncology (2025). PMID: 40965868 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Special Populations
  75. [75]

    Reyngold M, Schoenfeld JD, O'Reilly EM et al.. “Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy.” JAMA oncology (2025). PMID: 40208620 ↗

    L4OTHERCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations
  76. [76]

    Yuan C, Babic A, Khalaf N et al.. “Diabetes, Weight Change, and Pancreatic Cancer Risk.” JAMA oncology (2020). PMID: 32789511 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
  77. [77]

    Mavromatis LA, Zlatanic V, Agarunov E et al.. “Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer.” JAMA oncology (2026). PMID: 41885821 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Special Populations
  78. [78]

    Ding J, Edelmann D, Carlsson SV et al.. “Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer.” JAMA oncology (2026). PMID: 42133339 ↗

    L2OTHERCited in: Definition and Epidemiology
  79. [79]

    Tao J, Pfeiffer RM, Ahmed S et al.. “Cancer Risk in Solid Organ Transplant Recipients With a Pretransplant Cancer History.” JAMA oncology (2026). PMID: 41817522 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  80. [80]

    Burus T, Lei F, Huang B et al.. “Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic.” JAMA oncology (2024). PMID: 38386344 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  81. [81]

    van Roessel S, van Veldhuisen E, Klompmaker S et al.. “Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.” JAMA oncology (2020). PMID: 32910170 ↗

    L3OTHERCited in: Definition and Epidemiology, Management Overview
  82. [82]

    Reyngold M, O'Reilly EM, Varghese AM et al.. “Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer.” JAMA oncology (2021). PMID: 33704353 ↗

    L3OTHERCited in: Definition and Epidemiology, Management Overview
  83. [83]

    Carpenter ES, Elhossiny AM, Kadiyala P et al.. “Analysis of Donor Pancreata Defines the Transcriptomic Signature and Microenvironment of Early Neoplastic Lesions.” Cancer discovery (2023). PMID: 37021392 ↗

    L4OTHERCited in: Definition and Epidemiology, Histopathology and Molecular Biology
  84. [84]

    Kurz E, Hirsch CA, Dalton T et al.. “Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer.” Cancer cell (2022). PMID: 35660135 ↗

    L5OTHERCited in: Definition and Epidemiology, Management Overview
  85. [85]

    Xie X, Xia W, Li Z et al.. “Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models.” Cancer cell (2007). PMID: 17613436 ↗

    L5OTHERCited in: Definition and Epidemiology
  86. [86]

    Yokoyama S, Hamada T, Higashi M et al.. “Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31992588 ↗

    L3OTHERCited in: Definition and Epidemiology, Imaging, Staging, Prognosis and Prognostic Factors
  87. [87]

    Jonna S, Feldman RA, Swensen J et al.. “Detection of NRG1 Gene Fusions in Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30988082 ↗

    L3OTHERCited in: Definition and Epidemiology
  88. [88]

    Whatcott CJ, Diep CH, Jiang P et al.. “Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25695692 ↗

    L3OTHERCited in: Definition and Epidemiology
  89. [89]

    Luo H, England CG, Shi S et al.. “Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27026197 ↗

    L5OTHERCited in: Definition and Epidemiology, Imaging
  90. [90]

    Lu S, Zhang Z, Du P et al.. “A Virus-Infected, Reprogrammed Somatic Cell-Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31767564 ↗

    L5OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  91. [91]

    Tsang ES, Topham JT, Karasinska JM et al.. “Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32958704 ↗

    L3OTHERCited in: Definition and Epidemiology
  92. [92]

    Daly MB, Pal T, Berry MP et al.. “Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33406487 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Management Overview
  93. [93]

    Daly MB, Pilarski R, Yurgelun MB et al.. “NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32259785 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Management Overview
  94. [94]

    Stoffel EM, McKernin SE, Brand R et al.. “Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30457921 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  95. [95]

    Locker GY, Hamilton S, Harris J et al.. “ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 17060676 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Imaging, Molecular Diagnostics and Biomarkers
  96. [96]

    Park JH, Hong JY, Shen JJ et al.. “Smoking Cessation and Pancreatic Cancer Risk in Individuals With Prediabetes and Diabetes: A Nationwide Cohort Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37935099 ↗

    L2COHORTCited in: Risk Factors and Prevention
  97. [97]

    Maisonneuve P, Amar S, Lowenfels AB. “Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28453689 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  98. [98]

    Turati F, Galeone C, Edefonti V et al.. “A meta-analysis of coffee consumption and pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21746805 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  99. [99]

    Aune D, Greenwood DC, Chan DS et al.. “Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21890910 ↗

    L1SR_OBSCited in: Risk Factors and Prevention, Clinical Presentation
  100. [100]

    Casolino R, Paiella S, Azzolina D et al.. “Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34197182 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  101. [101]

    Leonhardt CS, Stamm T, Hank T et al.. “Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.” ESMO open (2023). PMID: 37988953 ↗

    L4SR_OBSCited in: Risk Factors and Prevention, Management Overview
  102. [102]

    Middleton G, Silcocks P, Cox T et al.. “Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.” The Lancet. Oncology (2014). PMID: 24954781 ↗

    L1RCTCited in: Risk Factors and Prevention, Clinical Presentation
  103. [103]

    Pearson C, Jones DA, Baily G et al.. “Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.” The Lancet. Oncology (2026). PMID: 41713471 ↗

    L3COHORTCited in: Risk Factors and Prevention, Clinical Presentation, Staging
  104. [104]

    van 't Land FR, Willemsen M, Bezemer K et al.. “Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38950309 ↗

    L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention, Management Overview, Special Populations
  105. [105]

    Ott PA, Bang YJ, Piha-Paul SA et al.. “T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30557521 ↗

    L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  106. [106]

    Bidoli E, Pelucchi C, Zucchetto A et al.. “Fiber intake and pancreatic cancer risk: a case-control study.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21460379 ↗

    L3CASE_CONTROLCited in: Risk Factors and Prevention, Special Populations
  107. [107]

    Waterhouse M, Risch HA, Bosetti C et al.. “Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25977560 ↗

    L3CASE_CONTROLCited in: Risk Factors and Prevention, Clinical Presentation, Special Populations
  108. [108]

    Pelucchi C, Rosato V, Bracci PM et al.. “Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case-Control Consortium (PanC4).” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27836886 ↗

    L3CASE_CONTROLCited in: Risk Factors and Prevention
  109. [109]

    Duell EJ, Lucenteforte E, Olson SH et al.. “Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4).” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22767586 ↗

    L3CASE_CONTROLCited in: Risk Factors and Prevention
  110. [110]

    Lucenteforte E, La Vecchia C, Silverman D et al.. “Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4).” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21536662 ↗

    L3CASE_CONTROLCited in: Risk Factors and Prevention
  111. [111]

    Sarno F, Tenorio J, Perea S et al.. “A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39540844 ↗

    L1RCTCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Special Populations
  112. [112]

    Chantrill LA, Nagrial AM, Watson C et al.. “Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25896973 ↗

    L4RCTCited in: Risk Factors and Prevention, Histopathology and Molecular Biology
  113. [113]

    Misek DE, Patwa TH, Lubman DM et al.. “Early detection and biomarkers in pancreatic cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2007). PMID: 18053427 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  114. [114]

    Daly MB, Pilarski R, Axilbund JE et al.. “Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 26850485 ↗

    L1OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology
  115. [115]

    Zhao Y, Wang Z, Xu M et al.. “Chemoprophylaxis effect of EGCG on various digestive system diseases: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42359071 ↗

    L5SR_OBSCited in: Risk Factors and Prevention
  116. [116]

    Yuan C, Kim J, Wang QL et al.. “The age-dependent association of risk factors with pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35398288 ↗

    L2OTHERCited in: Risk Factors and Prevention
  117. [117]

    Dores GM, Curtis RE, van Leeuwen FE et al.. “Pancreatic cancer risk after treatment of Hodgkin lymphoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25185241 ↗

    L3OTHERCited in: Risk Factors and Prevention, Special Populations
  118. [118]

    Stoop TF, Croce C, Ishida H et al.. “Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international multicentre retrospective study.” BJS open (2026). PMID: 42263216 ↗

    L3COHORTCited in: Risk Factors and Prevention, Clinical Presentation, Management Overview, Special Populations
  119. [119]

    Daniel F, Abdallah B, Chaitou AR et al.. “Association between postoperative Clostridioides difficile infection and outcomes following pancreatoduodenectomy for pancreatic cancer: a national cohort study.” Surgical endoscopy (2026). PMID: 42257924 ↗

    L3COHORTCited in: Risk Factors and Prevention, Management Overview, Special Populations
  120. [120]

    Zhang A, Zhu X, Li Z et al.. “Type 2 Diabetes, Glycemic Traits and Overall Cancer Risk: A Large-Scale Prospective Cohort Study.” Cancer medicine (2026). PMID: 42144703 ↗

    L2COHORTCited in: Risk Factors and Prevention
  121. [121]

    Ando Y, Dbouk M, Yoshida T et al.. “Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38457748 ↗

    L3OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  122. [122]

    Heestand GM, Murphy JD, Lowy AM. “Approach to patients with pancreatic cancer without detectable metastases.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25918279 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Prognosis and Prognostic Factors
  123. [123]

    Stoffel EM. “Screening in GI Cancers: The Role of Genetics.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25918283 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  124. [124]

    Genkinger JM, Klein AP. “Why Is Earlier Detection, the Key to Reducing Pancreatic Cancer, So Challenging Despite Technological Advances?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40743485 ↗

    L5OTHERCited in: Risk Factors and Prevention
  125. [125]

    Hassan MM, Li D, El-Deeb AS et al.. “Association between hepatitis B virus and pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18824707 ↗

    L3OTHERCited in: Risk Factors and Prevention
  126. [126]

    Yuan C, Bao Y, Wu C et al.. “Prediagnostic body mass index and pancreatic cancer survival.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24145341 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  127. [127]

    Abdullah M, Zaheer A, Lodhi BA et al.. “Effectiveness of multidisciplinary team collaboration in focal pancreatic lesion management: a systematic review.” Abdominal radiology (New York) (2026). PMID: 42257900 ↗

    L2SR_OBSCited in: Risk Factors and Prevention, Clinical Presentation, Imaging
  128. [128]

    Petrelli F, Dottorini L, Celotti A et al.. “Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes.” Cancer treatment reviews (2026). PMID: 42341370 ↗

    L2REVIEW_NARRATIVECited in: Risk Factors and Prevention
  129. [129]

    Custodio A, Puente J, Sastre J et al.. “Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.” Cancer treatment reviews (2009). PMID: 19758760 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Special Populations
  130. [130]

    Sideras K, Braat H, Kwekkeboom J et al.. “Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.” Cancer treatment reviews (2013). PMID: 24315741 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  131. [131]

    Mahmood U, Carrier E, Khan K. “Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma - Heading towards a promising change in treatment paradigm.” Cancer treatment reviews (2024). PMID: 38703592 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  132. [132]

    Berger JM, Alany A, Puhr R et al.. “Clinical risk factors for ascites in metastatic pancreatic cancer.” ESMO open (2023). PMID: 36989885 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Management Overview
  133. [133]

    Russo A, Incorvaia L, Capoluongo E et al.. “Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies.” ESMO open (2022). PMID: 35597177 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview
  134. [134]

    Peacock HM, Tambuyzer T, Verdoodt F et al.. “Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis.” ESMO open (2021). PMID: 34474811 ↗

    L2OTHERCited in: Risk Factors and Prevention
  135. [135]

    Huntley C, Torr B, Sud A et al.. “Utility of polygenic risk scores in UK cancer screening: a modelling analysis.” The Lancet. Oncology (2023). PMID: 37178708 ↗

    L2REVIEW_NARRATIVECited in: Risk Factors and Prevention
  136. [136]

    Cheng HH, Shevach JW, Castro E et al.. “BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.” JAMA oncology (2024). PMID: 39052257 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview
  137. [137]

    Inamdar S, Slattery E, Bhalla R et al.. “Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort.” JAMA oncology (2016). PMID: 26513013 ↗

    L2OTHERCited in: Risk Factors and Prevention, Prognosis and Prognostic Factors
  138. [138]

    Mano R, Tamir S, Kedar I et al.. “Malignant Abnormalities in Male BRCA Mutation Carriers: Results From a Prospectively Screened Cohort.” JAMA oncology (2018). PMID: 29710070 ↗

    L2OTHERCited in: Risk Factors and Prevention
  139. [139]

    Sang W, Zhou Y, Chen H et al.. “Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer.” Cancer discovery (2024). PMID: 37824278 ↗

    L5OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Management Overview
  140. [140]

    Wang X, Wang H, Zhang M et al.. “Development and Prospective Validation of a Cell-free DNA-Based Model for the Early Detection of Pancreatic Cancer.” Cancer discovery (2026). PMID: 40982573 ↗

    L3OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Molecular Diagnostics and Biomarkers, Special Populations
  141. [141]

    Zhou T, Yan J, Mao G et al.. “Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring.” Cancer discovery (2026). PMID: 41891402 ↗

    L5OTHERCited in: Risk Factors and Prevention
  142. [142]

    Heining C, Horak P, Uhrig S et al.. “NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.” Cancer discovery (2018). PMID: 29802158 ↗

    L4OTHERCited in: Risk Factors and Prevention, Prognosis and Prognostic Factors
  143. [143]

    Hegde S, Krisnawan VE, Herzog BH et al.. “Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.” Cancer cell (2020). PMID: 32183949 ↗

    L5OTHERCited in: Risk Factors and Prevention, Management Overview
  144. [144]

    Zheng C, Fass JN, Shih YP et al.. “Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers.” Cancer cell (2022). PMID: 35413272 ↗

    L4OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology
  145. [145]

    Hayes TK, Neel NF, Hu C et al.. “Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.” Cancer cell (2015). PMID: 26725216 ↗

    L5OTHERCited in: Risk Factors and Prevention
  146. [146]

    Tu YK, Liang YC, Wu YJ et al.. “The association between sodium-glucose cotransporter 2 inhibitor and risk of pancreatic cancer among patients with type 2 diabetes mellitus: A real-world cohort study.” Medicine (2026). PMID: 42332532 ↗

    L2COHORTCited in: Risk Factors and Prevention, Management Overview
  147. [147]

    Anderko RR, Bowman AE, Murthy P et al.. “Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41342881 ↗

    L4OTHERCited in: Risk Factors and Prevention
  148. [148]

    Zhang Y, Houchen CW, Li M. “Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35617521 ↗

    L5OTHERCited in: Risk Factors and Prevention
  149. [149]

    Effenberger KE, Schroeder C, Hanssen A et al.. “Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29559560 ↗

    L2OTHERCited in: Risk Factors and Prevention
  150. [150]

    Li D, Abbruzzese JL. “New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20647474 ↗

    L5OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  151. [151]

    Chu NJ, Armstrong TD, Jaffee EM. “Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25623216 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  152. [152]

    Alagesan B, Contino G, Guimaraes AR et al.. “Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25348516 ↗

    L5OTHERCited in: Risk Factors and Prevention
  153. [153]

    Verna EC, Hwang C, Stevens PD et al.. “Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20876795 ↗

    L2OTHERCited in: Risk Factors and Prevention
  154. [154]

    Chen H, Zhou W, Bian A et al.. “Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36374556 ↗

    L5OTHERCited in: Risk Factors and Prevention
  155. [155]

    Delcuratolo MD, Cocomazzi G, Beccia V et al.. “The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.” Biomedicines (2026). PMID: 42351835 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  156. [156]

    Karnan S, Ota A, Hasan MN et al.. “Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells.” Cell death & disease (2026). PMID: 42336821 ↗

    L5OTHERCited in: Risk Factors and Prevention
  157. [157]

    Grossman SA, Ellsworth S, Campian J et al.. “Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26483062 ↗

    L2SR_OBSCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors, Special Populations
  158. [158]

    Middleton G, Palmer DH, Greenhalf W et al.. “Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.” The Lancet. Oncology (2017). PMID: 28259610 ↗

    L1RCTCited in: Histopathology and Molecular Biology, Staging
  159. [159]

    Hyung J, Lee H, Jin H et al.. “Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX.” ESMO open (2022). PMID: 35576696 ↗

    L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
  160. [160]

    Tan HL, Zhao Y, Chua DW et al.. “Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials.” Surgery (2025). PMID: 41381268 ↗

    L1SR_MA_RCTCited in: Histopathology and Molecular Biology
  161. [161]

    Liebs S, Nonnenmacher A, Klauschen F et al.. “Liquid biopsy assessment of synchronous malignancies: a case report and review of the literature.” ESMO open (2019). PMID: 31555482 ↗

    L4CASE_REPORTCited in: Histopathology and Molecular Biology
  162. [162]

    Scarlato E, Dusetti N, Melisi D. “Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities.” Cancer treatment reviews (2026). PMID: 41886796 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Clinical Presentation, Molecular Diagnostics and Biomarkers
  163. [163]

    Fraunhoffer N, Hammel P, Conroy T et al.. “Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38906254 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Management Overview, Special Populations
  164. [164]

    Nicolle R, Gayet O, Duconseil P et al.. “A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33188873 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  165. [165]

    Hendifar AE, Krishna V, Krishna V et al.. “Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41671529 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  166. [166]

    Guo JA, Hoffman HI, Weekes CD et al.. “Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33653818 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  167. [167]

    Carrizosa DR, Rothe M, Mangat PK et al.. “Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” JCO precision oncology (2026). PMID: 41538762 ↗

    L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
  168. [168]

    Scott JG, Berglund A, Schell MJ et al.. “A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.” The Lancet. Oncology (2016). PMID: 27993569 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Staging
  169. [169]

    Bonù ML, Balduzzi J, Pedersoli G et al.. “Impact of Dosimetric Parameters on Tumor Control in Stereotactic Radiotherapy for Pancreatic Cancer: A Prospective Study on 104 Patients Treated with Simultaneous Integrated Protection (SIP).” Cancers (2025). PMID: 41300984 ↗

    L2COHORTCited in: Histopathology and Molecular Biology
  170. [170]

    Flowers BM, Xu H, Mulligan AS et al.. “Cell of Origin Influences Pancreatic Cancer Subtype.” Cancer discovery (2021). PMID: 34009137 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  171. [171]

    Ben-Shmuel A, Scherz-Shouval R. “Keeping IPMNs in Check: A Novel Role for the Transcription Factor NKX6-2 in Preserving an Indolent Cell Identity in Pancreatic Cystic Lesions.” Cancer discovery (2023). PMID: 37539476 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  172. [172]

    Chen SH, Zhang Y, Van Horn RD et al.. “Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.” Cancer discovery (2016). PMID: 26732095 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  173. [173]

    Li J, Yuan S, Norgard RJ et al.. “Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.” Cancer discovery (2020). PMID: 33158848 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  174. [174]

    Chen MM, Gao Q, Ning H et al.. “Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer.” Cancer cell (2025). PMID: 40680743 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  175. [175]

    . “Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.” Cancer cell (2017). PMID: 28810144 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  176. [176]

    Di Chiaro P, Nacci L, Arco F et al.. “Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer.” Cancer cell (2024). PMID: 38518775 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  177. [177]

    Connor AA, Denroche RE, Jang GH et al.. “Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases.” Cancer cell (2019). PMID: 30686769 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
  178. [178]

    Wang L, Heidt DG, Lee CJ et al.. “Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization.” Cancer cell (2009). PMID: 19249679 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Clinical Presentation
  179. [179]

    Facciorusso A, Bellocchi MCC, De Pretis N et al.. “Endoscopic Ultrasound-guided Fine-Needle Biopsy With End-Cutting Needles in Autoimmune Pancreatitis: A Systematic Review and Meta-Analysis.” DEN open (2025). PMID: 41195006 ↗

    L1SR_OBSCited in: Histopathology and Molecular Biology
  180. [180]

    . “Recruited Nerves Supply Serine to Support Pancreatic Cancer Growth.” Cancer discovery (2020). PMID: 33188053 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  181. [181]

    Mota J, Ribeiro T, Conti Bellocchi MC et al.. “Endoscopic ultrasound through-the-needle biopsy of pancreatic cystic neoplasms: Update on indications, safety profile, and research directions.” Best practice & research. Clinical gastroenterology (2025). PMID: 42167851 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
  182. [182]

    Wang J, Luo W, Zhang M et al.. “Artificial intelligence: Catalyzing a new era in pancreatic cancer cure.” Cancer letters (2026). PMID: 42081963 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  183. [183]

    Zhu Y, Ma K, Hao Q et al.. “The RNA methylation modification as an immunometabolic regulatory hub in pancreatic cancer: from mechanistic insights to clinical translation perspectives.” Molecular cancer (2026). PMID: 42021253 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  184. [184]

    Capurso G, Garajova I, Neuzillet C et al.. “Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41846177 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  185. [185]

    Di Martino M, Ministrini S, Tiberio G et al.. “Liver resection for noncolorectal liver metastases: the good, the bad, and the ugly.” Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2026). PMID: 41825768 ↗

    L2REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  186. [186]

    D'Empaire Altimari DM, Bevere M, Espinet E et al.. “Molecular subtypes in pancreatic cancer: from academic promise to clinical reality.” Molecular cancer (2026). PMID: 41796340 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  187. [187]

    Loveless IM, Kemp SB, Hartway KM et al.. “Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39636224 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  188. [188]

    Lee JJ, Bernard V, Semaan A et al.. “Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34426439 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
  189. [189]

    León-Letelier RA, Chen Y, Dou R et al.. “Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40184234 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Special Populations
  190. [190]

    Donahue TR, Tran LM, Hill R et al.. “Integrative survival-based molecular profiling of human pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22261810 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  191. [191]

    Yu J, Li A, Hong SM et al.. “MicroRNA alterations of pancreatic intraepithelial neoplasias.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 22114139 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  192. [192]

    Liu M, Yang J, Zhang Y et al.. “ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29615456 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Staging
  193. [193]

    Dey P, Rachagani S, Chakraborty S et al.. “Overexpression of ecdysoneless in pancreatic cancer and its role in oncogenesis by regulating glycolysis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22977192 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  194. [194]

    Kikuchi S, Honda K, Tsuda H et al.. “Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18765526 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  195. [195]

    Chida K, Kawazoe A, Suzuki T et al.. “Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35254400 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  196. [196]

    Li X, Truty MA, Kang Y et al.. “Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25336691 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  197. [197]

    Guo K, Cui J, Quan M et al.. “The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27449499 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  198. [198]

    Lee J, Condello S, Yakubov B et al.. “Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26041746 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  199. [199]

    Cui J, Shi M, Xie D et al.. “FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24634381 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  200. [200]

    Frisch A, Martin E, Cannon T et al.. “Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies.” Current oncology (Toronto, Ont.) (2026). PMID: 41892176 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  201. [201]

    Cicala A, Dziadowicz SA, Westcott PMK. “A pancreatic intraepithelial neoplasia-Oramic view of early pancreatic cancer in 3D.” Trends in immunology (2026). PMID: 42265012 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  202. [202]

    Li R, Xu X, Zhang W et al.. “Single-cell and spatial transcriptomic profiling reveals the expression characteristics of PTPRR in epithelial cells and its potential implications in pancreatic cancer metastasis.” Frontiers in immunology (2026). PMID: 42212130 ↗

    L4OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
  203. [203]

    Powers J, Wei L, Cheung JCT et al.. “eIF4G2-Dependent Translation Restrains Pancreatic Cancer Progression.” Cancer research (2026). PMID: 42202060 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  204. [204]

    Tempero MA, Malafa MP, Al-Hawary M et al.. “Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33845462 ↗

    L1GUIDELINECited in: Clinical Presentation, Management Overview
  205. [205]

    Tempero MA, Malafa MP, Al-Hawary M et al.. “Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28784865 ↗

    L1GUIDELINECited in: Clinical Presentation, Staging, Management Overview, Prognosis and Prognostic Factors
  206. [206]

    Tempero MA, Arnoletti JP, Behrman SW et al.. “Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.” Journal of the National Comprehensive Cancer Network : JNCCN (2012). PMID: 22679115 ↗

    L1GUIDELINECited in: Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors
  207. [207]

    Sohal DPS, Kennedy EB, Khorana A et al.. “Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29791286 ↗

    L1GUIDELINECited in: Clinical Presentation
  208. [208]

    Neuzillet C, Bouché O, Tournigand C et al.. “Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 38081120 ↗

    L1RCTCited in: Clinical Presentation, Management Overview
  209. [209]

    Tai D, Conroy T, Lee JJX et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer.” ESMO open (2025). PMID: 41067164 ↗

    L1GUIDELINECited in: Clinical Presentation, Management Overview
  210. [210]

    Suker M, Beumer BR, Sadot E et al.. “FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.” The Lancet. Oncology (2016). PMID: 27160474 ↗

    L1SR_OBSCited in: Clinical Presentation, Staging, Management Overview, Prognosis and Prognostic Factors
  211. [211]

    Kempers MJ, Kuiper RP, Ockeloen CW et al.. “Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study.” The Lancet. Oncology (2010). PMID: 21145788 ↗

    L2COHORTCited in: Clinical Presentation
  212. [212]

    Groarke JD, Crawford J, Collins SM et al.. “Ponsegromab for the Treatment of Cancer Cachexia.” The New England journal of medicine (2024). PMID: 39282907 ↗

    L1RCTCited in: Clinical Presentation, Management Overview, Special Populations
  213. [213]

    Al-Samkari H, Muñoz C, Geredeli Ç et al.. “Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.” The New England journal of medicine (2026). PMID: 41812193 ↗

    L1RCTCited in: Clinical Presentation, Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  214. [214]

    Cecchini M, Salem RR, Robert M et al.. “Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 38900452 ↗

    L4RCTCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  215. [215]

    Sohal DPS, Duong M, Ahmad SA et al.. “Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33475684 ↗

    L1RCTCited in: Clinical Presentation, Management Overview
  216. [216]

    Lawrence YR, Miszczyk M, Dawson LA et al.. “Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2024). PMID: 39029483 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  217. [217]

    Lakhani NJ, Chow LQM, Gainor JF et al.. “Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.” The Lancet. Oncology (2021). PMID: 34793719 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  218. [218]

    Alistar A, Morris BB, Desnoyer R et al.. “Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.” The Lancet. Oncology (2017). PMID: 28495639 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation
  219. [219]

    Schram AM, Goto K, Kim DW et al.. “Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.” The New England journal of medicine (2025). PMID: 39908431 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  220. [220]

    Chen L, Davelaar J, Gaddam S et al.. “Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36395704 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Special Populations
  221. [221]

    McPhail S, Barclay ME, Johnson SA et al.. “Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study.” The Lancet. Oncology (2024). PMID: 38423048 ↗

    L2SR_OBSCited in: Clinical Presentation, Special Populations
  222. [222]

    Gilbert JW, Wolpin B, Clancy T et al.. “Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28407088 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging, Management Overview
  223. [223]

    Kleger A, Perkhofer L, Seufferlein T. “Smarter drugs emerging in pancreatic cancer therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24631947 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview, Special Populations
  224. [224]

    Duffy MJ, Sturgeon C, Lamerz R et al.. “Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19690057 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  225. [225]

    Bosetti C, Rosato V, Li D et al.. “Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25057164 ↗

    L3CASE_CONTROLCited in: Clinical Presentation
  226. [226]

    Zogopoulos G, Haimi I, Sanoba SA et al.. “The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38626807 ↗

    L2OTHERCited in: Clinical Presentation, Imaging
  227. [227]

    Al-Hawary M. “Role of Imaging in Diagnosing and Staging Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27226513 ↗

    L5OTHERCited in: Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors
  228. [228]

    Seelen LWF, Augustinus S, Stoop TF et al.. “Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 39970867 ↗

    L2OTHERCited in: Clinical Presentation, Staging, Prognosis and Prognostic Factors, Special Populations
  229. [229]

    Tempero M. “Active Systemic Treatment of Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28515255 ↗

    L5OTHERCited in: Clinical Presentation, Management Overview
  230. [230]

    Boucher Y, Posada JM, Subudhi S et al.. “Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36749873 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation
  231. [231]

    De Dosso S, Siebenhüner AR, Winder T et al.. “Treatment landscape of metastatic pancreatic cancer.” Cancer treatment reviews (2021). PMID: 33812339 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
  232. [232]

    Pliarchopoulou K, Pectasides D. “Pancreatic cancer: current and future treatment strategies.” Cancer treatment reviews (2009). PMID: 19328630 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  233. [233]

    Prades J, Arnold D, Brunner T et al.. “Bratislava Statement: consensus recommendations for improving pancreatic cancer care.” ESMO open (2020). PMID: 33188052 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  234. [234]

    Taieb J, Prager GW, Melisi D et al.. “First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study.” ESMO open (2020). PMID: 31958291 ↗

    L4REVIEW_NARRATIVECited in: Clinical Presentation
  235. [235]

    Rangelova E, Stoop TF, van Ramshorst TME et al.. “The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39814200 ↗

    L4OTHERCited in: Clinical Presentation, Management Overview, Special Populations
  236. [236]

    Du W, Zhou Y, Huang H et al.. “Diagnostic value of EUS-guided tissue acquisition in suspected autoimmune pancreatitis: A 15-year single-center retrospective study.” Endoscopic ultrasound (2026). PMID: 42292789 ↗

    L4COHORTCited in: Clinical Presentation
  237. [237]

    Yang R, Sun Y, An R et al.. “Head to head comparison of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT in the diagnosis and staging of pancreatic cancer: a prospective study.” EJNMMI research (2026). PMID: 42249240 ↗

    L2COHORTCited in: Clinical Presentation, Imaging
  238. [238]

    Wexler RP. “The Liver We Share.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 42048617 ↗

    L5OTHERCited in: Clinical Presentation
  239. [239]

    Yuan C, Morales-Oyarvide V, Babic A et al.. “Cigarette Smoking and Pancreatic Cancer Survival.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28358654 ↗

    L2OTHERCited in: Clinical Presentation
  240. [240]

    Yuan C, Qian ZR, Babic A et al.. “Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27325858 ↗

    L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  241. [241]

    Yuan C, Rubinson DA, Qian ZR et al.. “Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25403204 ↗

    L2OTHERCited in: Clinical Presentation
  242. [242]

    Wei D, Wang L, Liu Y et al.. “CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40757874 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
  243. [243]

    Kiehl F, De Lazzari N, Beller R et al.. “High-Intensity Interval Training Boosts Immune Cells in Advanced Cancer Patients and Healthy Controls: Implications for Cancer Care.” Cancer medicine (2026). PMID: 42233178 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Special Populations
  244. [244]

    Mizuma M, Hirakawa S, Tachimori H et al.. “Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study using the Japan Pancreatic Cancer Registry.” Pancreas (2026). PMID: 42348544 ↗

    L4COHORTCited in: Clinical Presentation
  245. [245]

    Ikushima H, Watanabe K, Shinozaki-Ushiku A et al.. “Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data.” ESMO open (2025). PMID: 40138743 ↗

    L4OTHERCited in: Clinical Presentation, Special Populations
  246. [246]

    Keyl J, Bucher A, Jungmann F et al.. “Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter study.” ESMO open (2024). PMID: 38194881 ↗

    L4OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors
  247. [247]

    Berger JM, Alany A, Berchtold L et al.. “Prognosticators of survival in patients with metastatic pancreatic cancer and ascites.” ESMO open (2023). PMID: 37977000 ↗

    L4OTHERCited in: Clinical Presentation, Management Overview
  248. [248]

    Keyl J, Kasper S, Wiesweg M et al.. “Multimodal survival prediction in advanced pancreatic cancer using machine learning.” ESMO open (2022). PMID: 35988455 ↗

    L4OTHERCited in: Clinical Presentation, Imaging, Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  249. [249]

    Reissig TM, Tzianopoulos I, Liffers ST et al.. “Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.” ESMO open (2023). PMID: 37148593 ↗

    L4OTHERCited in: Clinical Presentation, Management Overview
  250. [250]

    Pishvaian MJ, Blais EM, Brody JR et al.. “Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.” The Lancet. Oncology (2020). PMID: 32135080 ↗

    L4OTHERCited in: Clinical Presentation, Management Overview, Special Populations
  251. [251]

    Zeng C, Bastarache LA, Tao R et al.. “Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases.” JAMA oncology (2022). PMID: 35446370 ↗

    L2OTHERCited in: Clinical Presentation
  252. [252]

    O'Connor CA, Harrold E, Lin D et al.. “Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer.” JAMA oncology (2024). PMID: 39235819 ↗

    L3OTHERCited in: Clinical Presentation, Management Overview, Special Populations
  253. [253]

    Unger JM, Fisch MJ, Jones SMW et al.. “Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy.” JAMA oncology (2026). PMID: 41452615 ↗

    L2OTHERCited in: Clinical Presentation, Management Overview
  254. [254]

    Fonteneau G, Redding A, Hoag-Lee H et al.. “Stress Granules Determine the Development of Obesity-Associated Pancreatic Cancer.” Cancer discovery (2022). PMID: 35674408 ↗

    L5OTHERCited in: Clinical Presentation
  255. [255]

    Mullen KM, Hong J, Attiyeh MA et al.. “The Evolutionary Forest of Pancreatic Cancer.” Cancer discovery (2025). PMID: 39378050 ↗

    L3OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  256. [256]

    Tsui WHA, Lo YMD. “Checking Up on the King of Cancers.” Cancer discovery (2026). PMID: 41521773 ↗

    L5OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  257. [257]

    Incio J, Liu H, Suboj P et al.. “Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.” Cancer discovery (2016). PMID: 27246539 ↗

    L5OTHERCited in: Clinical Presentation
  258. [258]

    Lee KE, Spata M, Bayne LJ et al.. “Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.” Cancer discovery (2015). PMID: 26715642 ↗

    L5OTHERCited in: Clinical Presentation, Staging, Prognosis and Prognostic Factors
  259. [259]

    Liu M, Ren Y, Zhou Z et al.. “The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.” Cancer cell (2024). PMID: 38608702 ↗

    L5OTHERCited in: Clinical Presentation
  260. [260]

    McIntyre CA, Grimont A, Park J et al.. “Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.” Cancer cell (2024). PMID: 39214094 ↗

    L3OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors, Special Populations
  261. [261]

    Kerzel T, Giacca G, Beretta S et al.. “In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases.” Cancer cell (2023). PMID: 37863068 ↗

    L5OTHERCited in: Clinical Presentation, Management Overview
  262. [262]

    Kureshi CTS, Walsh MJ, Kureshi R et al.. “Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer.” Cancer cell (2026). PMID: 42102812 ↗

    L5OTHERCited in: Clinical Presentation
  263. [263]

    Von Hoff DD, Korn R, Mousses S. “Pancreatic cancer--could it be that simple? A different context of vulnerability.” Cancer cell (2009). PMID: 19573807 ↗

    L5OTHERCited in: Clinical Presentation, Imaging
  264. [264]

    Rashid NU, Peng XL, Jin C et al.. “Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31754050 ↗

    L3OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  265. [265]

    Zhao T, Jiang T, Li X et al.. “Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37819952 ↗

    L5OTHERCited in: Clinical Presentation, Management Overview
  266. [266]

    Korc M. “Pancreatic cancer-associated diabetes is an "exosomopathy".” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25645860 ↗

    L5OTHERCited in: Clinical Presentation
  267. [267]

    Wang H, Maitra A, Wang H. “Obesity, Intrapancreatic Fatty Infiltration, and Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25995340 ↗

    L5OTHERCited in: Clinical Presentation
  268. [268]

    Romero JM, Grünwald B, Jang GH et al.. “A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31964786 ↗

    L3OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis
  269. [269]

    Staal B, Liu Y, Barnett D et al.. “The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30617132 ↗

    L3OTHERCited in: Clinical Presentation
  270. [270]

    Cazes A, Betancourt O, Esparza E et al.. “A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33451980 ↗

    L5OTHERCited in: Clinical Presentation
  271. [271]

    Chauffert B, Mornex F, Bonnetain F et al.. “Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 18467316 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis, Staging
  272. [272]

    Sinn M, Sinn BV, Striefler JK et al.. “SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24562449 ↗

    L2RCTCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  273. [273]

    Cuneo KC, Morgan MA, Sahai V et al.. “Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31398082 ↗

    L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  274. [274]

    Jabbar KS, Arike L, Verbeke CS et al.. “Highly Accurate Identification of Cystic Precursor Lesions of Pancreatic Cancer Through Targeted Mass Spectrometry: A Phase IIc Diagnostic Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29166170 ↗

    L3TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  275. [275]

    Wang Y, Cuggia A, Pacis A et al.. “Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34416708 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
  276. [276]

    Javle M, Shacham-Shmueli E, Xiao L et al.. “Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.” JAMA oncology (2021). PMID: 33662100 ↗

    L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Special Populations
  277. [277]

    Kanwar N, Seyi AB, Tan N et al.. “From Diagnosis, Therapy Decision-Making to Genetic Risk Assessment: The Impact of ctDNA Testing on Comprehensive Cancer Management-A Case Report.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671451 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  278. [278]

    Castillo J, Bernard V, San Lucas FA et al.. “Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29045505 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  279. [279]

    Lee B, Lipton L, Cohen J et al.. “Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31250894 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  280. [280]

    Mellby LD, Nyberg AP, Johansen JS et al.. “Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30106639 ↗

    L3OTHERCited in: Biopsy and Histologic Diagnosis
  281. [281]

    Infante JR, Matsubayashi H, Sato N et al.. “Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17235047 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  282. [282]

    Seeber A, Zimmer K, Kocher F et al.. “Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.” ESMO open (2020). PMID: 33229504 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  283. [283]

    Silva T, Yamazaki T, Creasy JM et al.. “The Differential Impact of Neoadjuvant Therapies on the Tumor Microenvironment, Peripheral Biomarkers, and Survival in Pancreatic Cancer: A Retrospective Cohort Study.” Cancers (2026). PMID: 42192927 ↗

    L2COHORTCited in: Biopsy and Histologic Diagnosis
  284. [284]

    Li K, Tandurella JA, Gai J et al.. “Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy.” Cancer cell (2022). PMID: 36306792 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Management Overview
  285. [285]

    Jena A, Dhar J, Dell'Anna G et al.. “Endoscopic Ultrasound fine-needle aspiration and cystic fluid analysis in patients with pancreatic cystic lesions.” Best practice & research. Clinical gastroenterology (2026). PMID: 42167855 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  286. [286]

    Carrara S, Bevere M, Delle Cave D et al.. “Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41866258 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  287. [287]

    Yao G, Zhang Y, Li H et al.. “Circulating Tumor DNA as a Biomarker in Pancreatic Cancer: Clinical Applications and Challenges.” Clinical and translational gastroenterology (2026). PMID: 41718013 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  288. [288]

    Hussain MM, Qammar S, Wang JM et al.. “Toward Timely Diagnosis of Pancreatic Cancer: Revolutionizing Early Detection Through Genomics, Artificial Intelligence, and Noninvasive Biomarkers.” Journal of gastroenterology and hepatology (2026). PMID: 41692706 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  289. [289]

    Pimenova M, Rosenbaum MW. “Cytology and small biopsy diagnosis of pancreatic ductal adenocarcinoma.” Seminars in diagnostic pathology (2026). PMID: 41653565 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  290. [290]

    Wang L, Chen Z, He X et al.. “Research progress on early diagnostic markers for pancreatic cancer.” World journal of surgical oncology (2026). PMID: 41588412 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  291. [291]

    Sharma SK, Mack KN, Piersigilli A et al.. “ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 34907079 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  292. [292]

    Khorana AA, Ahrendt SA, Ryan CK et al.. “Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17504985 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  293. [293]

    Strouch MJ, Cheon EC, Salabat MR et al.. “Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20371681 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  294. [294]

    Gao C, Wisniewski L, Liu Y et al.. “Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33093149 ↗

    L3OTHERCited in: Biopsy and Histologic Diagnosis
  295. [295]

    Collisson EA. “Distinctions with a Difference: RNA Subtyping and Clinical Outcome in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32661068 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis
  296. [296]

    Kim H, Saka B, Knight S et al.. “Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24486587 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  297. [297]

    Michaels AD, Newhook TE, Adair SJ et al.. “CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 29288236 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis, Staging
  298. [298]

    Bausch D, Thomas S, Mino-Kenudson M et al.. “Plectin-1 as a novel biomarker for pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 21098698 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  299. [299]

    Ni C, Xu J, Pang Y et al.. “Case Report: Converting an immunologically "cold" tumor: exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma.” Frontiers in immunology (2026). PMID: 42358962 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Management Overview
  300. [300]

    Ramanathan RK, Goldstein D, Korn RL et al.. “Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26802153 ↗

    L1RCTCited in: Imaging, Prognosis and Prognostic Factors
  301. [301]

    Wyse JM, Carone M, Paquin SC et al.. “Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21844506 ↗

    L1RCTCited in: Imaging
  302. [302]

    Picozzi V, Alseidi A, Winter J et al.. “Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer.” ESMO open (2020). PMID: 32817130 ↗

    L2RCTCited in: Imaging, Special Populations
  303. [303]

    Ko AH, Dito E, Schillinger B et al.. “Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2005). PMID: 16344320 ↗

    L4TRIAL_NONRANDOMCited in: Imaging
  304. [304]

    Von Hoff DD, Ramanathan RK, Borad MJ et al.. “Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21969517 ↗

    L2TRIAL_NONRANDOMCited in: Imaging
  305. [305]

    Heinrich S, Pestalozzi BC, Schäfer M et al.. “Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18487569 ↗

    L4TRIAL_NONRANDOMCited in: Imaging
  306. [306]

    Conroy T, Castan F, Lopez A et al.. “Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.” JAMA oncology (2022). PMID: 36048453 ↗

    L1RCTCited in: Imaging, Management Overview
  307. [307]

    Murthy P, Zenati MS, AlMasri SS et al.. “Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 38150819 ↗

    L3OTHERCited in: Imaging, Management Overview
  308. [308]

    Martin RCG, Scheon E, Govindarajan N et al.. “pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic Cancer.” Pancreas (2026). PMID: 41941588 ↗

    L1GUIDELINECited in: Imaging, Prognosis and Prognostic Factors
  309. [309]

    Lohrmann C, O'Reilly EM, O'Donoghue JA et al.. “Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31540979 ↗

    L4TRIAL_NONRANDOMCited in: Imaging
  310. [310]

    Memon M, Chatzielefthreiou E, Kowal MR et al.. “The impact of MRI on real-world staging pathways and management timelines in pancreatic cancer: A systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41996777 ↗

    L1SR_OBSCited in: Imaging, Staging, Prognosis and Prognostic Factors
  311. [311]

    Stefanidis D, Grove KD, Schwesinger WH et al.. “The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review.” Annals of oncology : official journal of the European Society for Medical Oncology (2005). PMID: 16236756 ↗

    L5REVIEW_NARRATIVECited in: Imaging, Staging, Prognosis and Prognostic Factors
  312. [312]

    Humphris JL, Chang DK, Johns AL et al.. “The prognostic and predictive value of serum CA19.9 in pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22241899 ↗

    L3OTHERCited in: Imaging, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  313. [313]

    Ramanathan RK, Korn RL, Chiorean EG et al.. “Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27240995 ↗

    L5OTHERCited in: Imaging
  314. [314]

    Verslype C, Van Cutsem E, Dicato M et al.. “The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17600091 ↗

    L5OTHERCited in: Imaging, Staging
  315. [315]

    Hajj C, Goodman KA. “Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25918298 ↗

    L5REVIEW_NARRATIVECited in: Imaging, Molecular Diagnostics and Biomarkers
  316. [316]

    Dekker EN, van Dam JL, Janssen QP et al.. “Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38315954 ↗

    L3OTHERCited in: Imaging
  317. [317]

    Vasen H, Ibrahim I, Ponce CG et al.. “Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27114589 ↗

    L2OTHERCited in: Imaging
  318. [318]

    Pedrazzoli S. “Extent of lymphadenectomy to associate with pancreaticoduodenectomy in patients with pancreatic head cancer for better tumor staging.” Cancer treatment reviews (2015). PMID: 26045226 ↗

    L5REVIEW_NARRATIVECited in: Imaging, Staging
  319. [319]

    Alves N, Schuurmans M, Rutkowski D et al.. “Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study.” The Lancet. Oncology (2025). PMID: 41275871 ↗

    L2OTHERCited in: Imaging, Special Populations
  320. [320]

    Schmitz D, Yazdi F, Claaßen K et al.. “Prevalence and natural course of MRI-diagnosed dilated main pancreatic duct: A longitudinal, population-based prospective cohort study with a ten-year follow-up.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41927409 ↗

    L2COHORTCited in: Imaging
  321. [321]

    Gupta M, Choi H, Kemp SB et al.. “Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40260640 ↗

    L4OTHERCited in: Imaging
  322. [322]

    Asano H, Elhelaly AE, Hyodo F et al.. “Deuterium Magnetic Resonance Imaging Using Deuterated Water-Induced 2H-Tissue Labeling Allows Monitoring Cancer Treatment at Clinical Field Strength.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37732903 ↗

    L4OTHERCited in: Imaging
  323. [323]

    Payen T, Oberstein PE, Saharkhiz N et al.. “Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31831559 ↗

    L4OTHERCited in: Imaging, Staging
  324. [324]

    Heid I, Steiger K, Trajkovic-Arsic M et al.. “Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27663591 ↗

    L4OTHERCited in: Imaging
  325. [325]

    Kato S, Adashek JJ, Shaya J et al.. “Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33472910 ↗

    L4OTHERCited in: Imaging, Staging
  326. [326]

    Henry KE, Dacek MM, Dilling TR et al.. “A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30228208 ↗

    L5OTHERCited in: Imaging
  327. [327]

    Moroz A, Wang YH, Sharib JM et al.. “Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32341034 ↗

    L5OTHERCited in: Imaging
  328. [328]

    Tan BH, Birdsell LA, Martin L et al.. “Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19887488 ↗

    L2OTHERCited in: Imaging
  329. [329]

    Potjer TP, Schot I, Langer P et al.. “Variation in precursor lesions of pancreatic cancer among high-risk groups.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 23172884 ↗

    L2OTHERCited in: Imaging
  330. [330]

    Henke LE, Kim H, Laugeman E et al.. “Stereotactic Adaptive Radiation Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer to Minimize Gastrointestinal Toxicity (ARTIA-Pancreas): Protocol for a Single-Arm Prospective Trial.” JMIR research protocols (2026). PMID: 41730182 ↗

    L4TRIAL_NONRANDOMCited in: Imaging
  331. [331]

    Gherghescu CG, Baz RA, Dina C et al.. “Serum Biomarkers and CT-Derived Muscle Indices in Sarcopenia Associated with Pancreatic Neoplasm: A Comparative Clinical Study.” Chirurgia (Bucharest, Romania : 1990) (2026). PMID: 42084250 ↗

    L1RCTCited in: Imaging
  332. [332]

    Duggal S, Kalas M, Eldesouki MH et al.. “Role of Endoscopic Ultrasonography in Management of Pancreaticobiliary Cancers: Recent Trends and Advances.” Cancers (2026). PMID: 42352399 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  333. [333]

    Tsai CJ, Lin PY, Ong KH et al.. “Evaluating the prognostic significance of lymph node yield in resected pancreatic adenocarcinoma: a population-based study.” World journal of surgical oncology (2026). PMID: 42343361 ↗

    L2OTHERCited in: Imaging
  334. [334]

    Yamaguchi T, Sofue K, Masuda A et al.. “Deep Learning Detection of Direct and Indirect Imaging Findings Associated with Pancreatic Cancer at Contrast-enhanced and Noncontrast CT.” Radiology (2026). PMID: 42301012 ↗

    L3OTHERCited in: Imaging
  335. [335]

    Wu C, Tian B, Yang J. “A Naples prognostic score-based nomogram enhances perioperative risk stratification for resected pancreatic cancer.” Future oncology (London, England) (2026). PMID: 42287173 ↗

    L3OTHERCited in: Imaging
  336. [336]

    Eder AC, Wielenberg CF, Omrane MA et al.. “First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [68Ga]Ga-BCY18469 in pancreatic cancer patients: biodistribution, dosimetry and initial findings.” European journal of nuclear medicine and molecular imaging (2026). PMID: 42268404 ↗

    L4OTHERCited in: Imaging
  337. [337]

    Bidard FC, Huguet F, Louvet C et al.. “Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23676420 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  338. [338]

    Fuchs CS, Azevedo S, Okusaka T et al.. “A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25609246 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  339. [339]

    Chiorean EG, Von Hoff DD, Reni M et al.. “CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26802160 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  340. [340]

    Deplanque G, Demarchi M, Hebbar M et al.. “A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25858497 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  341. [341]

    Knox JJ, O'Kane G, King D et al.. “PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40929627 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  342. [342]

    Macarulla T, Pazo-Cid R, Guillén-Ponce C et al.. “Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30523758 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  343. [343]

    Liu JF, Moore KN, Birrer MJ et al.. “Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27793850 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  344. [344]

    Hartlapp I, Valta-Seufzer D, Siveke JT et al.. “Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113).” ESMO open (2022). PMID: 35970013 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  345. [345]

    Scarlato E, Merz V, Pietrobono S et al.. “Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial.” ESMO open (2026). PMID: 42090751 ↗

    L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Special Populations
  346. [346]

    Christensen TD, Maag E, Theile S et al.. “Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma.” ESMO open (2024). PMID: 38838501 ↗

    L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  347. [347]

    Hess V, Glimelius B, Grawe P et al.. “CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.” The Lancet. Oncology (2008). PMID: 18249033 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  348. [348]

    Huffman BM, Diossy M, Yurgelun MB et al.. “A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41686836 ↗

    L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  349. [349]

    Tempero MA. “NCCN Guidelines Updates: Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31117041 ↗

    L1OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  350. [350]

    San Lucas FA, Allenson K, Bernard V et al.. “Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26681674 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers
  351. [351]

    Yin L, Cao C, Lin J et al.. “Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40311105 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  352. [352]

    Lee CJ, Dosch J, Simeone DM. “Pancreatic cancer stem cells.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18539958 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  353. [353]

    Ko AH. “Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25918299 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  354. [354]

    Brozos-Vázquez E, Toledano-Fonseca M, Costa-Fraga N et al.. “Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.” Cancer treatment reviews (2024). PMID: 38490088 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
  355. [355]

    Jones L, Cunningham D, Starling N. “HER-2 directed therapies across gastrointestinal tract cancers - A new frontier.” Cancer treatment reviews (2024). PMID: 38959629 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
  356. [356]

    El Maalouf G, Le Tourneau C, Batty GN et al.. “Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.” Cancer treatment reviews (2008). PMID: 19027240 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  357. [357]

    Nishizaki D, Kurzrock R, Miyashita H et al.. “Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.” ESMO open (2024). PMID: 38503143 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations
  358. [358]

    Jordheim LP, Sève P, Trédan O et al.. “The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.” The Lancet. Oncology (2010). PMID: 21163702 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  359. [359]

    Mariussi M, Lima LCO, Ruelas MG et al.. “Irreversible electroporation combined with immunotherapy versus irreversible electroporation alone for locally advanced pancreatic cancer: a systematic review and meta-analysis.” Einstein (Sao Paulo, Brazil) (2026). PMID: 42054172 ↗

    L1SR_OBSCited in: Molecular Diagnostics and Biomarkers
  360. [360]

    Valero C, Lee M, Hoen D et al.. “Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.” JAMA oncology (2021). PMID: 33599686 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  361. [361]

    Maddipati R, Stanger BZ. “Pancreatic Cancer Metastases Harbor Evidence of Polyclonality.” Cancer discovery (2015). PMID: 26209539 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  362. [362]

    Schram AM, Odintsov I, Espinosa-Cotton M et al.. “Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.” Cancer discovery (2022). PMID: 35135829 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  363. [363]

    . “Targeting Macrophages Boosts Pancreatic Cancer Therapy.” Cancer discovery (2016). PMID: 27170064 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  364. [364]

    Huang YH, Hu J, Chen F et al.. “ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer.” Cancer discovery (2019). PMID: 31582374 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  365. [365]

    Hobbs GA, Baker NM, Miermont AM et al.. “Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.” Cancer discovery (2019). PMID: 31649109 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  366. [366]

    Kothari V, Wei I, Shankar S et al.. “Outlier kinase expression by RNA sequencing as targets for precision therapy.” Cancer discovery (2013). PMID: 23384775 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  367. [367]

    Wang Y, Lih TM, Lee JW et al.. “Multi-omic profiling of intraductal papillary neoplasms of the pancreas reveals distinct patterns and potential markers of progression.” Cancer cell (2025). PMID: 40882635 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations
  368. [368]

    Shukla SK, Purohit V, Mehla K et al.. “MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.” Cancer cell (2017). PMID: 28697344 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  369. [369]

    Singh H, Xiu J, Kapner KS et al.. “Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39283131 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  370. [370]

    Ozawa H, Takahashi K, Motegi T et al.. “Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 41086055 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  371. [371]

    Van Cutsem E, Collignon J, Eefsen RL et al.. “Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39385434 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  372. [372]

    Carpenter ES, Kadiyala P, Elhossiny AM et al.. “KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 37851080 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  373. [373]

    Yamamoto N, Dobersch S, Loveless I et al.. “HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39680021 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  374. [374]

    Oberg AL, Bamlet WR, Izmirlian G et al.. “Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41870276 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  375. [375]

    Yamamoto K, Iwase A, Maeda H. “Tumor-Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development.” Clinical and translational science (2026). PMID: 42257532 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  376. [376]

    Takrori E, Abdulmajid M, Devagudi D et al.. “Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy.” International journal of molecular sciences (2026). PMID: 42196390 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  377. [377]

    Bao W, Leng K, Xia X et al.. “Integrating single-cell analysis and digital pathology for risk stratification in pancreatic cancer.” Clinical & experimental metastasis (2026). PMID: 42189258 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers
  378. [378]

    Jung H, Park N, Kim J et al.. “Mass Spectrometry-Driven Proteomic Biomarkers for Serum-Based Detection of Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm-Associated Invasive Carcinoma.” Cancer medicine (2026). PMID: 42136141 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers
  379. [379]

    Lee J, Zhu Y, Tseng HR. “Bioorthogonal Click Chemistry-Enabled Enrichment of Extracellular Vesicles for Integrated Molecular and Functional Liquid Biopsy§.” Accounts of chemical research (2026). PMID: 42134309 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  380. [380]

    Sun W, Wang Y, Qiao X et al.. “Multiomics and Genomic Alteration Characterization Identifies VDAC1 as a Mitochondrial-Associated Biomarker in Pancreatic Cancer.” Human mutation (2026). PMID: 42111501 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers
  381. [381]

    Hong W. “Role of cancer-associated fibroblast-derived exosomes in pancreatic cancer: clinical therapeutic potential and targeting challenges.” Frontiers in immunology (2026). PMID: 42099594 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  382. [382]

    Bendell J, O'Reilly EM, Middleton MR et al.. “Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25573533 ↗

    L1RCTCited in: Staging
  383. [383]

    Löhr JM, Haas SL, Bechstein WO et al.. “Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21896540 ↗

    L1RCTCited in: Staging
  384. [384]

    Evans TRJ, Van Cutsem E, Moore MJ et al.. “Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27998964 ↗

    L1RCTCited in: Staging
  385. [385]

    Boeck S, Hoehler T, Seipelt G et al.. “Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17962204 ↗

    L1RCTCited in: Staging
  386. [386]

    Cunningham D, Chau I, Stocken DD et al.. “Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19858379 ↗

    L1RCTCited in: Staging
  387. [387]

    Hurwitz HI, Uppal N, Wagner SA et al.. “Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26351344 ↗

    L1RCTCited in: Staging
  388. [388]

    Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F et al.. “Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 23213101 ↗

    L1RCTCited in: Staging
  389. [389]

    Kulke MH, Tempero MA, Niedzwiecki D et al.. “Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19858396 ↗

    L1RCTCited in: Staging
  390. [390]

    Catenacci DV, Junttila MR, Karrison T et al.. “Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26527777 ↗

    L1RCTCited in: Staging
  391. [391]

    Herman JM, Wild AT, Wang H et al.. “Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23341531 ↗

    L1RCTCited in: Staging
  392. [392]

    Borad MJ, Reddy SG, Bahary N et al.. “Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25512461 ↗

    L1RCTCited in: Staging
  393. [393]

    Schorn S, Demir IE, Reyes CM et al.. “The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.” Cancer treatment reviews (2017). PMID: 28342938 ↗

    L1SR_OBSCited in: Staging
  394. [394]

    Meti N, Kelly D, Allen MJ et al.. “Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies.” Cancer treatment reviews (2021). PMID: 34757307 ↗

    L1SR_OBSCited in: Staging, Prognosis and Prognostic Factors
  395. [395]

    Du L, Wang-Gillam A. “Trends in Neoadjuvant Approaches in Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28784867 ↗

    L5REVIEW_NARRATIVECited in: Staging, Management Overview, Prognosis and Prognostic Factors
  396. [396]

    Lee J, Park SH, Chang HM et al.. “Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.” The Lancet. Oncology (2011). PMID: 22192731 ↗

    L1RCTCited in: Staging, Special Populations
  397. [397]

    Kordes S, Pollak MN, Zwinderman AH et al.. “Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.” The Lancet. Oncology (2015). PMID: 26067687 ↗

    L1RCTCited in: Staging, Special Populations
  398. [398]

    Starling N, Watkins D, Cunningham D et al.. “Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19858399 ↗

    L2TRIAL_NONRANDOMCited in: Staging
  399. [399]

    Evans DB, Varadhachary GR, Crane CH et al.. “Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18640930 ↗

    L2TRIAL_NONRANDOMCited in: Staging
  400. [400]

    Nywening TM, Wang-Gillam A, Sanford DE et al.. “Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.” The Lancet. Oncology (2016). PMID: 27055731 ↗

    L2TRIAL_NONRANDOMCited in: Staging
  401. [401]

    Rivera F, López-Tarruella S, Vega-Villegas ME et al.. “Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.” Cancer treatment reviews (2009). PMID: 19131170 ↗

    L5REVIEW_NARRATIVECited in: Staging
  402. [402]

    Du SQ, Liu YT, Yang F et al.. “Potential correlation between high SNHG expression and poor pancreatic cancer prognosis: evidence from systematic reviews and meta-analyses.” Cancer cell international (2026). PMID: 41654901 ↗

    L1SR_OBSCited in: Staging
  403. [403]

    D'Ambra V, Ricci C, Ingaldi C et al.. “Predictive factors for long-term survival in pancreatic ductal adenocarcinoma that underwent surgery: a systematic review and meta-analysis of literature.” Updates in surgery (2025). PMID: 40889102 ↗

    L1SR_OBSCited in: Staging
  404. [404]

    Ungureanu BS, Gheonea DI, Turcu-Stiolica A et al.. “Clinicopathologic relevance of EpCAM and CD44 in pancreatic cancer: insights from a meta-analysis.” Stem cell research & therapy (2025). PMID: 40866982 ↗

    L1SR_OBSCited in: Staging
  405. [405]

    Salcedo-Allende MT, Fuste Chimisana V, Zucchiatti Llanos AC et al.. “Position statement on the pathological assessment of pancreatic resection specimens in pancreatic ductal adenocarcinoma by the Societat Catalana de Pàncrees and the Societat Catalana d'Anatomia Patològica.” Gastroenterologia y hepatologia (2026). PMID: 41655901 ↗

    L1GUIDELINECited in: Staging
  406. [406]

    Kruger S, Heinemann V, Ross C et al.. “Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30346475 ↗

    L2OTHERCited in: Staging
  407. [407]

    Heinemann V. “Treatment of locoregional disease: adjuvant versus neoadjuvant.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22987951 ↗

    L5OTHERCited in: Staging
  408. [408]

    Malvezzi M, Bertuccio P, Rosso T et al.. “European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25623049 ↗

    L2OTHERCited in: Staging
  409. [409]

    Costa ACD, Duarte VA, Santa Cruz F et al.. “Pancreatoduodenectomy with vascular reconstruction versus chemotherapy alone in patients with locally advanced pancreatic cancer: a systematic review.” Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery (2025). PMID: 40767666 ↗

    L2SR_OBSCited in: Staging
  410. [410]

    Li H, Mo Z, Tong G. “Value of CRP, albumin, and lymphocyte index in predicting survival of patients with gastrointestinal malignancies: a systematic review and meta-analysis.” Frontiers in oncology (2025). PMID: 40740873 ↗

    L1SR_OBSCited in: Staging
  411. [411]

    Chang DK, Johns AL, Merrett ND et al.. “Margin clearance and outcome in resected pancreatic cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19398572 ↗

    L2OTHERCited in: Staging
  412. [412]

    Mokdad AA, Minter RM, Zhu H et al.. “Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27621388 ↗

    L2OTHERCited in: Staging
  413. [413]

    Borsati A, Toniolo L, Adamoli G et al.. “Structured Exercise During Chemotherapy for Locally Advanced or Metastatic Pancreatic Cancer: A Single-Arm, Feasibility Trial.” Cancer medicine (2026). PMID: 41700007 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  414. [414]

    Batist G, Kavan P, Augustin L et al.. “A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer.” Cancer immunology, immunotherapy : CII (2026). PMID: 41591505 ↗

    L3TRIAL_NONRANDOMCited in: Staging
  415. [415]

    Hong J, Kohutek ZA, Zhang H et al.. “Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer.” Cancer discovery (2026). PMID: 41650466 ↗

    L2OTHERCited in: Staging, Prognosis and Prognostic Factors
  416. [416]

    Wartenberg M, Cibin S, Zlobec I et al.. “Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29661773 ↗

    L2OTHERCited in: Staging
  417. [417]

    Shi M, Cui J, Du J et al.. “A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24947925 ↗

    L4OTHERCited in: Staging
  418. [418]

    Huang C, Li Y, Li Z et al.. “LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30679163 ↗

    L4OTHERCited in: Staging
  419. [419]

    Nixon AB, Pang H, Starr MD et al.. “Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24097873 ↗

    L2OTHERCited in: Staging
  420. [420]

    Pietrasz D, Pécuchet N, Garlan F et al.. “Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27993964 ↗

    L2OTHERCited in: Staging
  421. [421]

    Philip PA, Chansky K, LeBlanc M et al.. “Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24914040 ↗

    L2OTHERCited in: Staging
  422. [422]

    Cloyd JM, Colby S, Guthrie KA et al.. “Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38688309 ↗

    L1RCTCited in: Management Overview, Special Populations
  423. [423]

    Van Laethem JL, Verslype C, Iovanna JL et al.. “New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21810728 ↗

    L1GUIDELINECited in: Management Overview
  424. [424]

    Seufferlein T, Uhl W, Kornmann M et al.. “Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 36209981 ↗

    L1RCTCited in: Management Overview
  425. [425]

    Versteijne E, van Dam JL, Suker M et al.. “Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35084987 ↗

    L1RCTCited in: Management Overview
  426. [426]

    Versteijne E, Suker M, Groothuis K et al.. “Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32105518 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  427. [427]

    Kindler HL, Hammel P, Reni M et al.. “Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35834777 ↗

    L1RCTCited in: Management Overview
  428. [428]

    Ohba A, Ozaka M, Mizusawa J et al.. “Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40720715 ↗

    L1RCTCited in: Management Overview, Special Populations
  429. [429]

    Ducreux M, Desgrippes R, Rinaldi Y et al.. “PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40378359 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  430. [430]

    Oettle H, Riess H, Stieler JM et al.. “Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24982456 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  431. [431]

    Ueno H, Ioka T, Ikeda M et al.. “Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23547081 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  432. [432]

    Fietkau R, Ghadimi M, Grützmann R et al.. “Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40802908 ↗

    L1RCTCited in: Management Overview, Special Populations
  433. [433]

    Conroy T, Ducreux M. “ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer.” ESMO open (2025). PMID: 40287191 ↗

    L1GUIDELINECited in: Management Overview
  434. [434]

    Farge D, Frere C, Connors JM et al.. “2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.” The Lancet. Oncology (2022). PMID: 35772465 ↗

    L1GUIDELINECited in: Management Overview
  435. [435]

    Uson Junior PLS, Dias E Silva D, de Castro NM et al.. “Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials.” ESMO open (2023). PMID: 36638709 ↗

    L1SR_MA_RCTCited in: Management Overview
  436. [436]

    Chow R, Lage DE, Williams GR et al.. “Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 34991068 ↗

    L5SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  437. [437]

    Janssen QP, van Dam JL, van Bekkum ML et al.. “Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.” The Lancet. Oncology (2025). PMID: 40945523 ↗

    L1RCTCited in: Management Overview, Special Populations
  438. [438]

    Reiss KA, Mick R, Teitelbaum U et al.. “Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.” The Lancet. Oncology (2022). PMID: 35810751 ↗

    L1RCTCited in: Management Overview
  439. [439]

    Taniguchi CM, Frakes JM, Aguilera TA et al.. “Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.” The Lancet. Oncology (2023). PMID: 38039992 ↗

    L1RCTCited in: Management Overview, Special Populations
  440. [440]

    Conroy T, Desseigne F, Ychou M et al.. “FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.” The New England journal of medicine (2011). PMID: 21561347 ↗

    L1RCTCited in: Management Overview, Special Populations
  441. [441]

    Von Hoff DD, Ervin T, Arena FP et al.. “Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.” The New England journal of medicine (2013). PMID: 24131140 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  442. [442]

    Guillevin L, Pagnoux C, Karras A et al.. “Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.” The New England journal of medicine (2014). PMID: 25372085 ↗

    L1RCTCited in: Management Overview, Special Populations
  443. [443]

    Green JB, Bethel MA, Armstrong PW et al.. “Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2015). PMID: 26052984 ↗

    L1RCTCited in: Management Overview
  444. [444]

    Bai X, Li X, Chen Y et al.. “Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial.” Cancer cell (2025). PMID: 41072417 ↗

    L1RCTCited in: Management Overview, Special Populations
  445. [445]

    Mastrantoni L, Chiaravalli M, Spring A et al.. “Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.” The Lancet. Oncology (2024). PMID: 39542008 ↗

    L1SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors
  446. [446]

    Rahib L, Fleshman JM, Matrisian LM et al.. “Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review.” JAMA oncology (2016). PMID: 27270617 ↗

    L1TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors
  447. [447]

    Kaufman B, Shapira-Frommer R, Schmutzler RK et al.. “Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25366685 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  448. [448]

    Qi C, Zhang P, Liu C et al.. “Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38788174 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  449. [449]

    Pijnappel EN, Suurmeijer JA, Koerkamp BG et al.. “Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.” JAMA oncology (2022). PMID: 35446336 ↗

    L5SR_OBSCited in: Management Overview
  450. [450]

    Ruan DY, Liu FR, Wei XL et al.. “Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.” The Lancet. Oncology (2025). PMID: 39788133 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  451. [451]

    Musher BL, Rowinsky EK, Smaglo BG et al.. “LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.” The Lancet. Oncology (2024). PMID: 38547893 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  452. [452]

    Wolpin BM, Park W, Garrido-Laguna I et al.. “Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.” The New England journal of medicine (2026). PMID: 42090791 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  453. [453]

    Strickler JH, Satake H, George TJ et al.. “Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.” The New England journal of medicine (2022). PMID: 36546651 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors
  454. [454]

    Brahmer JR, Tykodi SS, Chow LQ et al.. “Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.” The New England journal of medicine (2012). PMID: 22658128 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  455. [455]

    Ghanem I, Lora D, Herradón N et al.. “Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.” ESMO open (2022). PMID: 35580504 ↗

    L1SR_OBSCited in: Management Overview
  456. [456]

    Herman JM, Hoffman JP, Thayer SP et al.. “Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26158133 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  457. [457]

    Rosso C, Marciano ND, Nathan D et al.. “Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38889755 ↗

    L3OTHERCited in: Management Overview, Special Populations
  458. [458]

    Chua YJ, Zalcberg JR. “Pancreatic cancer--is the wall crumbling?” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 18381371 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  459. [459]

    Mateo J, Lord CJ, Serra V et al.. “A decade of clinical development of PARP inhibitors in perspective.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31218365 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  460. [460]

    Tempero MA, Berlin J, Ducreux M et al.. “Pancreatic cancer treatment and research: an international expert panel discussion.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21199884 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  461. [461]

    Taieb J, Pointet AL, Van Laethem JL et al.. “What treatment in 2017 for inoperable pancreatic cancers?” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28459988 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  462. [462]

    Sahin IH, Askan G, Hu ZI et al.. “Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28945842 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  463. [463]

    Heinemann V, Haas M, Boeck S. “Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23852311 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  464. [464]

    Adjei AA. “Clinical studies of pemetrexed and gemcitabine combinations.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16807459 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  465. [465]

    Shindo K, Yu J, Suenaga M et al.. “Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28767289 ↗

    L3OTHERCited in: Management Overview
  466. [466]

    Szymczak-Pajor I, Drzewoski J, Wenclewska S et al.. “Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?” International journal of molecular sciences (2026). PMID: 42196179 ↗

    L1SR_OBSCited in: Management Overview
  467. [467]

    Henriksen A, Dyhl-Polk A, Chen I et al.. “Checkpoint inhibitors in pancreatic cancer.” Cancer treatment reviews (2019). PMID: 31325788 ↗

    L2REVIEW_NARRATIVECited in: Management Overview
  468. [468]

    van Kampen JG, Marijnissen-van Zanten MA, Simmer F et al.. “Epigenetic targeting in pancreatic cancer.” Cancer treatment reviews (2014). PMID: 24433955 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  469. [469]

    Lai E, Puzzoni M, Ziranu P et al.. “New therapeutic targets in pancreatic cancer.” Cancer treatment reviews (2019). PMID: 31739115 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  470. [470]

    Schizas D, Charalampakis N, Kole C et al.. “Immunotherapy for pancreatic cancer: A 2020 update.” Cancer treatment reviews (2020). PMID: 32247999 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  471. [471]

    Belli C, Cereda S, Anand S et al.. “Neoadjuvant therapy in resectable pancreatic cancer: a critical review.” Cancer treatment reviews (2012). PMID: 23122322 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  472. [472]

    Oehler C, Ciernik IF. “Radiation therapy and combined modality treatment of gastrointestinal carcinomas.” Cancer treatment reviews (2006). PMID: 16524667 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  473. [473]

    Heinemann V, Haas M, Boeck S. “Systemic treatment of advanced pancreatic cancer.” Cancer treatment reviews (2012). PMID: 22226241 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  474. [474]

    Dusetti N, Bachet JB, Chanez B et al.. “Medical management of pancreatic cancer: from personalization to broadening treatment strategies.” Cancer treatment reviews (2025). PMID: 40466554 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  475. [475]

    Catanese S, Pentheroudakis G, Douillard JY et al.. “ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer.” ESMO open (2020). PMID: 32423899 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  476. [476]

    Roeyen G, Berrevoet F, Borbath I et al.. “Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer.” ESMO open (2022). PMID: 35124465 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  477. [477]

    Webb N, Fricke J, Hancock E et al.. “The clinical and cost-effectiveness of supplemental parenteral nutrition in oncology.” ESMO open (2020). PMID: 32576610 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  478. [478]

    Koessler T, Alsina M, Arnold D et al.. “ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective.” ESMO open (2022). PMID: 35180656 ↗

    L5OTHERCited in: Management Overview
  479. [479]

    Leidner R, Sanjuan Silva N, Huang H et al.. “Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer.” The New England journal of medicine (2022). PMID: 35648703 ↗

    L4OTHERCited in: Management Overview
  480. [480]

    Canavan ME, Wang X, Ascha MS et al.. “Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors.” JAMA oncology (2024). PMID: 38753341 ↗

    L2OTHERCited in: Management Overview
  481. [481]

    Dilly J, Hoffman MT, Abbassi L et al.. “Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.” Cancer discovery (2024). PMID: 38975874 ↗

    L4OTHERCited in: Management Overview
  482. [482]

    Dominguez CX, Müller S, Keerthivasan S et al.. “Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy.” Cancer discovery (2019). PMID: 31699795 ↗

    L5OTHERCited in: Management Overview, Prognosis and Prognostic Factors
  483. [483]

    Tiriac H, Belleau P, Engle DD et al.. “Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.” Cancer discovery (2018). PMID: 29853643 ↗

    L4OTHERCited in: Management Overview
  484. [484]

    Singhal A, Styers HC, Rub J et al.. “A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer.” Cancer discovery (2024). PMID: 38975873 ↗

    L5OTHERCited in: Management Overview
  485. [485]

    Kemp SB, Cheng N, Markosyan N et al.. “Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.” Cancer discovery (2023). PMID: 36472553 ↗

    L5OTHERCited in: Management Overview
  486. [486]

    Belle JI, Sen D, Baer JM et al.. “Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer.” Cancer discovery (2024). PMID: 38683144 ↗

    L5OTHERCited in: Management Overview
  487. [487]

    Bianchi A, De Castro Silva I, Deshpande NU et al.. “Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer.” Cancer discovery (2023). PMID: 36946782 ↗

    L5OTHERCited in: Management Overview
  488. [488]

    McAndrews KM, Chen Y, Darpolor JK et al.. “Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.” Cancer discovery (2022). PMID: 35348629 ↗

    L5OTHERCited in: Management Overview
  489. [489]

    Yamaguchi N, Wu YG, Ravetch E et al.. “A Targetable Secreted Neural Protein Drives Pancreatic Cancer Metastatic Colonization and HIF1α Nuclear Retention.” Cancer discovery (2024). PMID: 39028915 ↗

    L5OTHERCited in: Management Overview
  490. [490]

    Schalck A, Sakellariou-Thompson D, Forget MA et al.. “Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer.” Cancer discovery (2022). PMID: 35849783 ↗

    L4OTHERCited in: Management Overview
  491. [491]

    Yuan L, Ji W, Dwyer BG et al.. “Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex.” Cancer discovery (2025). PMID: 40891634 ↗

    L5OTHERCited in: Management Overview
  492. [492]

    . “Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer.” Cancer discovery (2022). PMID: 35373275 ↗

    L5OTHERCited in: Management Overview
  493. [493]

    Ravichandran M, Hu J, Cai C et al.. “Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer.” Cancer discovery (2022). PMID: 35771494 ↗

    L5OTHERCited in: Management Overview
  494. [494]

    Renz BW, Takahashi R, Tanaka T et al.. “β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer.” Cancer cell (2017). PMID: 29249692 ↗

    L5OTHERCited in: Management Overview
  495. [495]

    Mucciolo G, Araos Henríquez J, Jihad M et al.. “EGFR-activated myofibroblasts promote metastasis of pancreatic cancer.” Cancer cell (2023). PMID: 38157863 ↗

    L5OTHERCited in: Management Overview
  496. [496]

    Bear AS, Vonderheide RH, O'Hara MH. “Challenges and Opportunities for Pancreatic Cancer Immunotherapy.” Cancer cell (2020). PMID: 32946773 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  497. [497]

    Mahadevan KK, McAndrews KM, LeBleu VS et al.. “KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells.” Cancer cell (2023). PMID: 37625401 ↗

    L5OTHERCited in: Management Overview
  498. [498]

    Riedl JM, Matsubara H, McNeil R et al.. “Emerging landscape of KRAS inhibitors in cancer treatment.” Cancer cell (2026). PMID: 41616774 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  499. [499]

    Liu X, Hogg GD, Zuo C et al.. “Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity.” Cancer cell (2023). PMID: 37236195 ↗

    L5OTHERCited in: Management Overview
  500. [500]

    Gabitova-Cornell L, Surumbayeva A, Peri S et al.. “Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer.” Cancer cell (2020). PMID: 32976774 ↗

    L5OTHERCited in: Management Overview
  501. [501]

    Du H, Hirabayashi K, Ahn S et al.. “Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.” Cancer cell (2019). PMID: 30753824 ↗

    L5OTHERCited in: Management Overview
  502. [502]

    Piper M, Hoen M, Darragh LB et al.. “Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.” Cancer cell (2023). PMID: 37116489 ↗

    L5OTHERCited in: Management Overview
  503. [503]

    Wei D, Wang L, Zuo X et al.. “A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 37831007 ↗

    L5OTHERCited in: Management Overview
  504. [504]

    Wehrli M, Guinn S, Birocchi F et al.. “Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38393682 ↗

    L5OTHERCited in: Management Overview
  505. [505]

    McVey JC, Beatty GL. “Facts and Hopes of CD40 Agonists in Cancer Immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40117130 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  506. [506]

    O'Kane GM, Grünwald BT, Jang GH et al.. “GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32156747 ↗

    L2OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  507. [507]

    Wang S, Yu G, Dai Y et al.. “IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V Mutation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40586688 ↗

    L5OTHERCited in: Management Overview
  508. [508]

    Singh H, Keller RB, Kapner KS et al.. “Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37463056 ↗

    L4OTHERCited in: Management Overview
  509. [509]

    Grossman JE, Muthuswamy L, Huang L et al.. “Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 34789479 ↗

    L2OTHERCited in: Management Overview
  510. [510]

    Steele NG, Biffi G, Kemp SB et al.. “Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33495315 ↗

    L5OTHERCited in: Management Overview
  511. [511]

    Cornwell AC, Tisdale AA, Venkat S et al.. “Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37587561 ↗

    L4OTHERCited in: Management Overview
  512. [512]

    Manji GA, Olive KP, Saenger YM et al.. “Current and Emerging Therapies in Metastatic Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28373365 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  513. [513]

    Korc M. “Heparin Prowess: Favorable Vascular-Immune Reprogramming in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37099035 ↗

    L5OTHERCited in: Management Overview
  514. [514]

    Richter A, Heidenhain C. “Robotic portomesenteric vein reconstruction using self-fashioned bovine pericardial grafts during Da Vinci-assisted pancreatectomy: a case series with video demonstration.” Surgical endoscopy (2026). PMID: 42257970 ↗

    L4CASE_REPORTCited in: Management Overview
  515. [515]

    Schmiechen ZC, Cruz-Hinojoza E, Hilk AL et al.. “Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer.” Science immunology (2026). PMID: 42361199 ↗

    L5OTHERCited in: Management Overview
  516. [516]

    Wei Z, Liu X, Zhang Z et al.. “Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy.” Oncology research (2026). PMID: 42358845 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  517. [517]

    Kuramochi T, Itaya T, Sano M et al.. “High-Dose Tramadol Enhances the Proliferative and Invasive Potential of Pancreatic Ductal Adenocarcinoma in Mice Through Microenvironmental Alteration.” Pain research & management (2026). PMID: 42325112 ↗

    L5OTHERCited in: Management Overview
  518. [518]

    Dickey EM, Marsh HM, Rydberg-Millrud C et al.. “IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancer.” JCI insight (2026). PMID: 42325091 ↗

    L5OTHERCited in: Management Overview
  519. [519]

    Cao Z, Qiu J, Luo W et al.. “Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study.” Signal transduction and targeted therapy (2026). PMID: 42324245 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  520. [520]

    Li F, Fu J, Lin X et al.. “Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer.” Oncology reports (2026). PMID: 42318966 ↗

    L5OTHERCited in: Management Overview
  521. [521]

    Bincoletto V, Andreana I, Stella B et al.. “Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer.” Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology (2026). PMID: 42312894 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  522. [522]

    Hammel P, Kindler HL, Reni M et al.. “Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31562758 ↗

    L1RCTCited in: Prognosis and Prognostic Factors
  523. [523]

    Karasic TB, O'Hara MH, Loaiza-Bonilla A et al.. “Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.” JAMA oncology (2019). PMID: 31120501 ↗

    L1RCTCited in: Prognosis and Prognostic Factors, Special Populations
  524. [524]

    Chung V, McDonough S, Philip PA et al.. “Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.” JAMA oncology (2017). PMID: 27978579 ↗

    L1RCTCited in: Prognosis and Prognostic Factors, Special Populations
  525. [525]

    Rahma OE, Duffy A, Liewehr DJ et al.. “Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23670093 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  526. [526]

    Vogel A, Ciardiello F, Hubner RA et al.. “Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.” Cancer treatment reviews (2016). PMID: 27676174 ↗

    L5SR_OBSCited in: Prognosis and Prognostic Factors
  527. [527]

    Pokataev I, Fedyanin M, Polyanskaya E et al.. “Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies.” ESMO open (2020). PMID: 33551067 ↗

    L2SR_OBSCited in: Prognosis and Prognostic Factors
  528. [528]

    Ter Veer E, van Rijssen LB, Besselink MG et al.. “Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.” The Lancet. Oncology (2018). PMID: 29508762 ↗

    L1SR_OBSCited in: Prognosis and Prognostic Factors
  529. [529]

    Weiss L, Fischer LE, Heinemann V et al.. “Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.” ESMO open (2024). PMID: 38503144 ↗

    L1TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations
  530. [530]

    Murphy JE, Wo JY, Ryan DP et al.. “Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.” JAMA oncology (2019). PMID: 31145418 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  531. [531]

    Lindström O, Udd M, Grönroos J et al.. “Covered self-expandable metal stents in benign biliary strictures caused by chronic pancreatitis: a randomized controlled trial of 6 versus 12 months of stenting.” Surgical endoscopy (2026). PMID: 42151467 ↗

    L1RCTCited in: Prognosis and Prognostic Factors, Special Populations
  532. [532]

    Ishigaki K, Nakai Y, Kashiwabara K et al.. “Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis of the randomized clinical trial (JASPAC-01).” Journal of gastroenterology (2026). PMID: 41991754 ↗

    L2RCTCited in: Prognosis and Prognostic Factors, Special Populations
  533. [533]

    Costamagna G, Reddy DN, Chia NH et al.. “Preoperative Biliary Drainage with Metal Stent Versus Early Surgery in Patients with Pancreatic Cancer: A Randomized Clinical Trial.” Annals of surgical oncology (2026). PMID: 41951900 ↗

    L1RCTCited in: Prognosis and Prognostic Factors
  534. [534]

    Golan T, Sella T, Margalit O et al.. “Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993-2013.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28784864 ↗

    L2OTHERCited in: Prognosis and Prognostic Factors
  535. [535]

    Golan T, Javle M. “DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28784866 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  536. [536]

    Hester CA, Perri G, Prakash LR et al.. “Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35948035 ↗

    L2OTHERCited in: Prognosis and Prognostic Factors
  537. [537]

    Corcoran RB, Do KT, Kim JE et al.. “Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38456660 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations
  538. [538]

    Li ZT, Sun ML, Liu FH et al.. “Prognostic Nutritional Index and Cancer Prognostic Outcomes: An Umbrella Review of Systematic Reviews and Meta-analyses of Observational Studies.” Advances in nutrition (Bethesda, Md.) (2026). PMID: 42001952 ↗

    L2SR_OBSCited in: Prognosis and Prognostic Factors
  539. [539]

    Peddakota V, Chikkala B, Kottapalli MA et al.. “Short-Term Outcomes of Arterial Divestment in Pancreatic Cancer: A Systematic Review and Single Arm Meta-Analysis of Observational Studies.” World journal of surgery (2026). PMID: 41903157 ↗

    L2SR_OBSCited in: Prognosis and Prognostic Factors
  540. [540]

    Mandalà M, Reni M, Cascinu S et al.. “Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17660490 ↗

    L2OTHERCited in: Prognosis and Prognostic Factors
  541. [541]

    Uzunoglu FG, Kolbe J, Wikman H et al.. “VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23293110 ↗

    L2OTHERCited in: Prognosis and Prognostic Factors
  542. [542]

    Malvezzi M, Carioli G, Bertuccio P et al.. “European cancer mortality predictions for the year 2019 with focus on breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30887043 ↗

    L2OTHERCited in: Prognosis and Prognostic Factors
  543. [543]

    Kanbayashi Y, Ishikawa T, Kawachi H et al.. “Predictors of long-term anamorelin hydrochloride use in patients with cancer cachexia: a single-center real-world retrospective study.” Future oncology (London, England) (2026). PMID: 41869701 ↗

    L2COHORTCited in: Prognosis and Prognostic Factors
  544. [544]

    Park W, O'Connor CA, Chou JF et al.. “Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.” Nature medicine (2026). PMID: 41882405 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  545. [545]

    Urman A, Ding Y, Durham J et al.. “Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma.” Frontiers in immunology (2026). PMID: 41878443 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  546. [546]

    Oettle H. “Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside.” Cancer treatment reviews (2014). PMID: 25087471 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  547. [547]

    Gaya A, Tse V. “A preclinical and clinical review of aflibercept for the management of cancer.” Cancer treatment reviews (2012). PMID: 22264850 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  548. [548]

    Verbeke C, Löhr M, Karlsson JS et al.. “Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties.” Cancer treatment reviews (2014). PMID: 25434282 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  549. [549]

    Macchini M, Centonze F, Peretti U et al.. “Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.” Cancer treatment reviews (2022). PMID: 35184001 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  550. [550]

    Heinemann V, Reni M, Ychou M et al.. “Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.” Cancer treatment reviews (2013). PMID: 23849556 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  551. [551]

    Ahn DH, Williams TM, Goldstein DA et al.. “Adjuvant therapy for pancreas cancer in an era of value based cancer care.” Cancer treatment reviews (2015). PMID: 26620819 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  552. [552]

    Kruger SF, Lohneis A, Abendroth A et al.. “Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study.” ESMO open (2022). PMID: 35121522 ↗

    L3OTHERCited in: Prognosis and Prognostic Factors
  553. [553]

    Hartwig W, Werner J, Jäger D et al.. “Improvement of surgical results for pancreatic cancer.” The Lancet. Oncology (2013). PMID: 24079875 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
  554. [554]

    . “Ruxolitinib Benefits Some with Pancreatic Cancer.” Cancer discovery (2015). PMID: 26463833 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  555. [555]

    . “Pancreatic Cancer Survival Increases with Chemo Combo.” Cancer discovery (2016). PMID: 27363975 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  556. [556]

    Miyabayashi K, Baker LA, Deschênes A et al.. “Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes.” Cancer discovery (2020). PMID: 32703770 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  557. [557]

    Alam A, Levanduski E, Denz P et al.. “Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer.” Cancer cell (2022). PMID: 35120601 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  558. [558]

    Steele CW, Karim SA, Leach JDG et al.. “CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.” Cancer cell (2016). PMID: 27265504 ↗

    L5OTHERCited in: Prognosis and Prognostic Factors
  559. [559]

    Leung PQ, Elghonaimy EA, Elamir AM et al.. “Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40310472 ↗

    L3OTHERCited in: Prognosis and Prognostic Factors, Special Populations
  560. [560]

    Cao L, Li H, Liu F et al.. “Risk Stratification and Prognosis Determination Based on Protein Lysine Crotonylation in Patients with Resected Pancreatic Cancer: A Multicenter Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40465840 ↗

    L3OTHERCited in: Prognosis and Prognostic Factors
  561. [561]

    Aune D, Chan DSM, Vieira AR et al.. “Dietary fructose, carbohydrates, glycemic indices and pancreatic cancer risk: a systematic review and meta-analysis of cohort studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22539563 ↗

    L2SR_OBSCited in: Special Populations
  562. [562]

    Macarulla T, Cid RP, Womack MS et al.. “NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.” ESMO open (2026). PMID: 41687160 ↗

    L1RCTCited in: Special Populations
  563. [563]

    Assenat E, de la Fouchardière C, Portales F et al.. “Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.” ESMO open (2021). PMID: 34837745 ↗

    L4RCTCited in: Special Populations
  564. [564]

    Mahalingam D, Saeed A, Powell SF et al.. “Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer.” ESMO open (2025). PMID: 40403387 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations
  565. [565]

    Rossi M, Lugo A, Lagiou P et al.. “Proanthocyanidins and other flavonoids in relation to pancreatic cancer: a case-control study in Italy.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 22052986 ↗

    L3CASE_CONTROLCited in: Special Populations
  566. [566]

    Mackay TM, van Rijssen LB, Andriessen JO et al.. “Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32502981 ↗

    L2OTHERCited in: Special Populations
  567. [567]

    Grierson PM, Wolf C, Suresh R et al.. “Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40125795 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations
  568. [568]

    Macchini M, Chiaravalli M, Zanon S et al.. “Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives.” Cancer treatment reviews (2018). PMID: 30414985 ↗

    L5REVIEW_NARRATIVECited in: Special Populations
  569. [569]

    Massaro M, Comito T, Franzese C et al.. “Adjuvant stereotactic pancreatic radiotherapy (SPARTA trial): interim safety analysis of an ongoing phase II single center prospective study.” Radiation oncology (London, England) (2026). PMID: 42129843 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations
  570. [570]

    Kanhailal AC, Knikman JE, Zielhuis SWJ et al.. “The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42114409 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations
  571. [571]

    Abdelrahim M, Khan G, Hatoum H et al.. “Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.” Future oncology (London, England) (2026). PMID: 42080361 ↗

    L1TRIAL_NONRANDOMCited in: Special Populations
  572. [572]

    Aguirre AJ, Nowak JA, Camarda ND et al.. “Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.” Cancer discovery (2018). PMID: 29903880 ↗

    L2OTHERCited in: Special Populations
  573. [573]

    Lesina M, Kurkowski MU, Ludes K et al.. “Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.” Cancer cell (2011). PMID: 21481788 ↗

    L5OTHERCited in: Special Populations

Revision History

All updates applied to this page

Loading revisions…